KR20130100255A - Novel compounds having arcridine structure and organic electroluminescence device using the same - Google Patents

Novel compounds having arcridine structure and organic electroluminescence device using the same Download PDF

Info

Publication number
KR20130100255A
KR20130100255A KR1020130101120A KR20130101120A KR20130100255A KR 20130100255 A KR20130100255 A KR 20130100255A KR 1020130101120 A KR1020130101120 A KR 1020130101120A KR 20130101120 A KR20130101120 A KR 20130101120A KR 20130100255 A KR20130100255 A KR 20130100255A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
group
compound
preparation
Prior art date
Application number
KR1020130101120A
Other languages
Korean (ko)
Other versions
KR101434798B1 (en
Inventor
백영미
김태형
박호철
Original Assignee
주식회사 두산
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 두산 filed Critical 주식회사 두산
Priority to KR1020130101120A priority Critical patent/KR101434798B1/en
Publication of KR20130100255A publication Critical patent/KR20130100255A/en
Application granted granted Critical
Publication of KR101434798B1 publication Critical patent/KR101434798B1/en

Links

Images

Classifications

    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
    • H10K50/12OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising dopants
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
    • H10K50/125OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers specially adapted for multicolour light emission, e.g. for emitting white light
    • H10K50/13OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers specially adapted for multicolour light emission, e.g. for emitting white light comprising stacked EL layers within one EL unit
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/631Amine compounds having at least two aryl rest on at least one amine-nitrogen atom, e.g. triphenylamine
    • H10K85/633Amine compounds having at least two aryl rest on at least one amine-nitrogen atom, e.g. triphenylamine comprising polycyclic condensed aromatic hydrocarbons as substituents on the nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

PURPOSE: A novel compound with an acridine structure is provided to show excellent brightness, power efficiency, heat resistance, and hole transporting and injecting performance, to enhance color purity and light emitting efficiency, and to be applied one or more among a hole injection layer, a hole transport layer, and a light emitting layer. CONSTITUTION: A compound is denoted by chemical formula 1. An organic electroluminescence device comprises an anode, a cathode, and one or more organic layers inserted between the anode and the cathode. One or more organic layers contain the compound. The organic layer is a light emitting layer.

Description

아크리딘 구조를 포함하는 신규한 화합물 및 이를 이용한 유기 전계 발광 소자{NOVEL COMPOUNDS HAVING ARCRIDINE STRUCTURE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME}TECHNICAL FIELD [0001] The present invention relates to a novel compound containing an acridine structure and an organic electroluminescent device using the same. BACKGROUND ART < RTI ID = 0.0 > [0002]

아크리딘 구조를 포함하는 신규한 화합물 및 이를 이용한 유기 전계 발광 소자용 화합물 및 이를 이용한 유기 전계 발광 소자에 관한 것으로, 보다 구체적으로 아크리딘 구조를 포함하는 신규한 화합물을 포함하여 발광효율, 휘도, 열적 안정성, 구동 전압, 수명 등의 특성이 향상된 유기 전계 발광 소자에 관한 것이다.The present invention relates to a novel compound containing an acridine structure and to an organic electroluminescent device using the compound and an organic electroluminescent device using the same. More particularly, the present invention relates to a novel compound containing an acridine structure, , Thermal stability, driving voltage, lifetime, and the like.

최근 정보 통신 산업의 발달이 가속화됨에 따라 가장 중요한 분야의 하나인 디스플레이 소자 분야에 있어서 보다 고도의 성능이 요구되고 있다. 이러한 디스플레이는 발광형과 비발광형으로 나눌 수 있다. 발광형에 속하는 디스플레이로는 음극 선관(Cathode Ray Tube: CRT), 전계 발광 소자(Electroluminescene Display: ELD), 전기 발광 다이오드(Light Emitting Diode: LED), 플라즈마 소자 패널 (Plazma Display Panel: PDP) 등이 있다. 그리고, 비발광형 디스플레이로는 액정디스플레이(Liquid Crystal Display: LCD) 등이 있다.Recently, as the development of the information and communication industry is accelerated, higher performance is required in the field of display devices, which is one of the most important fields. Such displays can be divided into luminescent and non-luminescent. Examples of displays belonging to the light emitting type include a cathode ray tube (CRT), an electroluminescence display (ELD), a light emitting diode (LED), a plasma display panel (PDP) have. Non-light emitting displays include liquid crystal displays (LCDs).

일반적으로 유기 전계 발광 현상이란 유기 물질을 이용하여 전기 에너지를 빛 에너지로 전환시켜 주는 현상을 말한다. 유기 전계 발광 현상을 이용하는 유기 전계 발광 소자는 통상 양극(anode)과 음극(cathode) 및 이들 사이에 유기물층을 포함하는 구조를 가진다. 여기서 유기물층은 유기 발광 소자의 효율과 안정성을 높이기 위하여 각기 다른 물질로 구성된 다층의 구조로 이루어진 경우가 많으며, 예컨대 정공 주입층, 정공 수송층, 발광층, 전자 수송층, 전자 주입층 등을 포함 할 수 있다.Generally, organic electroluminescent phenomenon refers to a phenomenon in which an organic material is used to convert electric energy into light energy. An organic electroluminescent device using organic electroluminescent phenomenon generally has a structure including an anode and a cathode and an organic layer between them. Here, in order to increase the efficiency and stability of the organic light emitting device, the organic material layer may have a multi-layer structure composed of different materials and may include a hole injection layer, a hole transport layer, a light emitting layer, an electron transport layer, and an electron injection layer.

1950년대 Bernanose의 유기 박막 발광 관측을 시점으로 1965년 안트라센 단결정을 이용한 청색 전기발광으로 이어진 유기 전계 발광 (electro luminescent, EL) 소자에 대한 연구는 1987년 탕(Tang)에 의하여 정공층과 발광층의 기능층으로 나눈 적층 구조의 유기 EL 소자가 제시되었고, 고효율, 고수명의 유기 전계 발광 소자를 만들기 위하여 소자 내 각각의 특징적인 유기물 층을 도입하는 형태로 발전하여 왔으며, 이에 사용되는 특화된 물질의 개발로 이어졌다.A study on the electro luminescent (EL) devices which led to the blue electroluminescence using the anthracene single crystal in 1965 based on the observation of the organic thin film emission of the 1950s Bernanose was carried out in 1987 by Tang in the function of the hole layer and the luminescent layer Layered organic EL device has been proposed. In order to make a high efficiency and high number of organic electroluminescent devices, each organic material layer has been developed into a form of introducing characteristic organic material layers, and the development of specialized materials used thereon has been continued .

이러한 유기 전계 발광 소자의 구조에서 두 전극 사이에 전압을 걸어 주면 양극에서는 정공이 주입되고, 음극에서는 전자가 유기물층으로 주입된다. 주입된 정공과 전자가 만났을 때 엑시톤(exciton)이 형성되며, 이 엑시톤이 바닥상태로 떨어질 때 빛이 나게 된다. 유기 전계 발광 소자에서 유기물층으로 사용되는 물질은 기능에 따라, 발광 물질, 정공 주입 물질, 정공 수송 물질, 전자 수송 물질, 전자 주입 물질 등으로 분류될 수 있다.In the structure of such an organic electroluminescent device, when a voltage is applied between two electrodes, holes are injected into the anode and electrons are injected into the organic layer at the cathode. When the injected holes and electrons meet, an exciton is formed. When the exciton falls to the ground state, light is emitted. A material used as an organic material layer in an organic electroluminescent device can be classified into a light emitting material, a hole injecting material, a hole transporting material, an electron transporting material, and an electron injecting material according to functions.

발광 물질은 발광색에 따라 청색, 녹색, 적색 발광 물질과 보다 나은 천연색을 구현하기 위해 필요한 노란색 및 주황색 발광 물질로 구분될 수 있다. 또한, 색순도의 증가와 에너지 전이를 통한 발광 효율을 증가시키기 위하여, 발광 물질로서 호스트/도판트(dopant)계를 사용할 수 있다. 그 원리는 발광층을 주로 구성하는 호스트보다 에너지 대역 간극이 작고 발광 효율이 우수한 도판트를 발광층에 소량 혼합하면, 호스트에서 발생한 엑시톤이 도판트로 수송되어 효율이 높은 빛을 내는 것이다. 이때 호스트의 파장이 도판트의 파장대로 이동하므로, 이용하는 도판트의 종류에 따라 원하는 파장의 빛을 얻을 수 있다.The luminescent material can be classified into blue, green and red luminescent materials according to luminescent colors and yellow and orange luminescent materials necessary for realizing better natural colors. In addition, a host / dopant system may be used as the light emitting material in order to increase the color purity and increase the luminous efficiency through energy transfer. The principle is that when a small amount of dopant having a smaller energy band gap and a higher luminous efficiency than a host mainly constituting the light emitting layer is mixed with the light emitting layer in a small amount, the excitons generated in the host are transported to the dopant to emit light with high efficiency. At this time, since the wavelength of the host is shifted to the wavelength band of the dopant, the desired wavelength light can be obtained depending on the type of the dopant used.

전자 수송 물질은 전자에 대한 안정도와 전자 이동 속도가 상대적으로 우수한 유기 금속착제들이 유기 단분자 물질로서 좋은 후보들이며, 안정성이 우수하고 전자 친화도가 큰 Alq3가 가장 우수한 것으로 보고 되었으며, 현재에도 가장 기본적으로 사용되고 있다. 또한, 종래에 공지된 전자 수송 물질로는 산요(Sanyo)사에서 발표한 플라본(flavon)유도체 또는 치소(Chisso)사의 게르마늄 및 실리콘시클로펜타디엔 유도체 등이 알려져 있다. (일본공개특허공보 제1998-017860호, 일본공개특허공보 제1999-087067호).It is reported that the organometallic complexes, which have relatively high stability and electron transfer rate, are good candidates for organic monomolecular materials, and that Alq3, which has excellent stability and electron affinity, is the most excellent. . Examples of conventionally known electron transport materials include flavon derivatives disclosed in Sanyo, or germanium and silicon cyclopentadiene derivatives of Chisso. (Japanese Unexamined Patent Publication No. 1998-017860, Japanese Unexamined Patent Publication No. 1999-087067).

현재까지 퀴놀린 착물 유도체에 관해서는 많은 연구가 이루어져 왔고 청색 발광층 재료로 이데미쓰-고산의 DPVBi(화학식 A) 이후로 많은 재료들이 개발되어 상업화되어 있으며, 이데미쓰-고산의 청색 재료 시스템과 코닥의 디나프틸안트라센(dinaphthylanthracen, 화학식 B) 등이 알려져 있으나, 아직도 많은 연구 개발이 이루어져야 할 것으로 판단된다.Much research has been conducted on quinoline complex derivatives to date and many materials have been developed and commercialized since the DPVBi (formula A) of Idemitsu-Gosan as a blue light emitting layer material, and the blue material system of Idemitsu- And dinaphthylanthracene (Formula B) are known, but many research and development efforts are still required.

[화학식 A](A)

Figure pat00001
Figure pat00001

[화학식 B][Formula B]

Figure pat00002
Figure pat00002

또한, 종래의 전자 주입 물질 및 전자 수송 물질로는 이미다졸기, 옥사졸기, 티아졸기를 가진 유기 단분자 물질들이 많이 보고되었다. 그러나 이러한 물질들이 전자수송용 물질로 보고되기 이전에 이러한 물질들의 금속착체 화합물들이 유기 전계 발광 소자의 청색 발광층 또는 청록색 발광층에 적용된 것으로 이미 보고되었다.In addition, organic monomolecular materials having an imidazole group, an oxazole group, and a thiazole group have been reported as conventional electron injecting materials and electron transporting materials. However, it has been reported that metal complex compounds of these materials are applied to a blue light emitting layer or a cyan light emitting layer of an organic electroluminescent device before such materials are reported as materials for electron transporting.

특히 도핑 재료는 발광 효율의 향상에 큰 영향을 주는 재료이나, 발광 효율, 호스트 물질과의 불일치 등의 이유로 그 개발에 어려움을 겪어 왔다. 청색의 도판트의 경우에는 스티릴 구조가 열적으로 안정하지 않아서 순도를 높이기 어려웠으며, 이에 따라 색순도가 떨어지고 효율이 낮아지거나 수명이 짧아지는 문제가 있었다. 또한, 짙은 청색의 색순도를 가지기 위해서는 도판트의 호모 (Homo)와 루모 (Lumo) 사이의 에너지 차이 (Band gap)가 커야 하는데 이러한 물질의 개발이 쉽지 않았다. 따라서 색순도, 효율 및 열안정성에 관해 연구 개발이 시급한 부분이라고 하겠다.In particular, doping materials have been difficult to develop due to reasons such as luminescent efficiency, inconsistency with a host material, and the like, which greatly affect the improvement of the luminous efficiency. In the case of the blue dopant, the styryl structure was not thermally stable and thus it was difficult to increase the purity. As a result, there was a problem that the color purity decreased and the efficiency became lower or the lifetime shortened. Also, in order to have a dark blue color purity, the energy gap between the homo and the lumo of the dopant must be large, and development of such a material is not easy. Therefore, it is urgent to research and develop color purity, efficiency and thermal stability.

1. 일본공개특허공보 제1998-017860호1. Japanese Laid-Open Patent Publication No. 1998-017860 2. 일본공개특허공보 제1999-087067호2. Japanese Laid-Open Patent Application No. 1999-087067

본 발명은 색순도, 발광효율, 휘도, 전력효율, 열적 안정성, 구동전압, 내열성, 소자 수명 등의 제반 특성이 향상된 신규한 유기 화합물을 제공하고자 한다. The present invention provides a novel organic compound having improved various characteristics such as color purity, luminous efficiency, luminance, power efficiency, thermal stability, driving voltage, heat resistance, and device lifetime.

본 발명은 상기 신규 유기 화합물을 포함하여 높은 색순도, 우수한 색 안정성, 낮은 구동전압 및 높은 효율을 나타내는 유기 전계 발광 소자를 제공하고자 한다.An object of the present invention is to provide an organic electroluminescent device including the novel organic compound exhibiting high color purity, excellent color stability, low driving voltage and high efficiency.

본 발명은 하기 화학식 1로 표시되는 화합물을 제공한다. The present invention provides a compound represented by the following formula (1).

[화학식 1][Formula 1]

Figure pat00003
Figure pat00003

상기 화학식 1에서, In Formula 1,

A 및 B는 각각 독립적으로 단일결합, 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기로 이루어진 군에서 선택되고;A and B are each independently selected from a single bond, a substituted or an aryl group of a beach C 6 ~ C 60 ring, and a substituted or unsubstituted C 3 ~ C 60 heteroaryl group consisting of a ring;

n은 0 또는 1이고, 단 n이 0 일때 상기 A 및 B가 동시에 단일결합인 경우를 제외하고;n is 0 or 1 except when A and B are simultaneously a single bond when n is 0;

Ar1 및 Ar2는 각각 독립적으로 하기 화학식 2 내지 화학식 4로 이루어진 군에서 선택되나, 상기 Ar1 및 Ar2가 동시에 화학식 4인 경우를 제외하고;Ar 1 and Ar 2 are each independently selected from the group consisting of the following formulas (2) to (4) except that Ar 1 and Ar 2 are simultaneously represented by formula (4);

[화학식 2](2)

Figure pat00004
Figure pat00004

[화학식 3](3)

Figure pat00005
Figure pat00005

[화학식 4][Formula 4]

Figure pat00006
Figure pat00006

R1 내지 R10은 각각 독립적으로 치환 혹은 비치환된 C1~C60의 알킬기, 치환 혹은 비치환된 C2~C60의 알케닐기, 치환 혹은 비치환된 C2~C60의 알키닐기, 치환 혹은 비치환된 C6~C60의 아릴기, 치환 혹은 비치환된 C3~C60의 헤테로아릴기, 치환 혹은 비치환된 C1~C60의 알콕시기, 치환 혹은 비치환된 C6~C60의 아릴옥시기, 치환 혹은 비치환된 C7~C60의 아릴알킬기, 치환 혹은 비치환된 C3~C60의 헤테로아릴알킬기, 치환 혹은 비치환된 C3~C60의 시클로알킬기, 치환 혹은 비치환된 C1~C60의 할로겐알킬기, 치환 혹은 비치환된 C1~C60의 헤테로시클로알킬기, 치환 혹은 비치환된 C3~C60 의 알킬실릴기, 치환 혹은 비치환된 C3~C60의 아릴실릴기, 및 치환 혹은 비치환된 C1~C60의 헤테로아릴실릴기로 이루어진 군에서 선택되고; Each of R 1 to R 10 independently represents a substituted or unsubstituted C 1 to C 60 alkyl group, a substituted or unsubstituted C 2 to C 60 alkenyl group, a substituted or unsubstituted C 2 to C 60 alkynyl group, A substituted or unsubstituted C 6 to C 60 aryl group, a substituted or unsubstituted C 3 to C 60 heteroaryl group, a substituted or unsubstituted C 1 to C 60 alkoxy group, a substituted or unsubstituted C 6 to C 60 aryl group, ~ C 60 of the aryloxy group, a substituted or unsubstituted C 7 ~ C 60 aryl group, a substituted or unsubstituted C 3 ~ C 60 heteroaryl group, a substituted or unsubstituted C 3 ~ cycloalkyl group of C 60 of the , A substituted or unsubstituted C 1 to C 60 halogenalkyl group, a substituted or unsubstituted C 1 to C 60 heterocycloalkyl group, a substituted or unsubstituted C 3 to C 60 alkylsilyl group, a substituted or unsubstituted A C 3 to C 60 arylsilyl group, and a substituted or unsubstituted C 1 to C 60 heteroarylsilyl group;

R1 내지 R8은 각각 인접하는 치환기와 융합(fused)되거나 고리를 형성할 수 있고;R 1 to R 8 may each be fused or may form a ring with adjacent substituents;

X1 내지 X5는 각각 독립적으로 수소, 중수소, 할로겐, 아미노기, 니트로기, 니트릴기, 치환 혹은 비치환된 C1~C60의 알킬기, 치환 혹은 비치환된 C2~C60의 알케닐기, 치환 혹은 비치환된 C2~C60의 알키닐기, 치환 혹은 비치환된 C6~C60의 아릴기, 치환 혹은 비치환된 C3~C60의 헤테로아릴기, 치환 혹은 비치환된 C1~C60의 알콕시기, 치환 혹은 비치환된 C6~C60의 아릴옥시기, 치환 혹은 비치환된 C6~C60의 알킬아미노기, 치환 혹은 비치환된 C6~C60의 아릴아미노기, 치환 혹은 비치환된 C6~C60의 디아릴아미노기, 치환 혹은 비치환된 C3~C60의 헤테로아릴아미노기, 치환 혹은 비치환된 C2~C60의 디헤테로아릴아미노기, 치환 혹은 비치환된 C7~C60의 아릴알킬기, 치환 혹은 비치환된 C3~C60의 헤테로아릴알킬기, 치환 혹은 비치환된 C3~C60의 시클로알킬기, 치환 혹은 비치환된 C1~C60의 할로겐알킬기, 치환 혹은 비치환된 C1~C60의 헤테로시클로알킬기, 치환 혹은 비치환된 C3~C60 의 알킬실릴기, 치환 혹은 비치환된 C3~C60의 아릴실릴기, 및 치환 혹은 비치환된 C1~C60의 헤테로아릴실릴기로 이루어진 군에서 선택되고;X 1 to X 5 each independently represent hydrogen, deuterium, a halogen, an amino group, a nitro group, a nitrile group, a substituted or unsubstituted C 1 to C 60 alkyl group, a substituted or unsubstituted C 2 to C 60 alkenyl group, A substituted or unsubstituted C 2 to C 60 alkynyl group, a substituted or unsubstituted C 6 to C 60 aryl group, a substituted or unsubstituted C 3 to C 60 heteroaryl group, a substituted or unsubstituted C 1 to C 60 heteroaryl group, ~ C 60 alkoxy group, a substituted or unsubstituted C 6 ~ C 60 of the aryloxy group, a substituted or unsubstituted C 6 ~ C 60 alkyl group, a substituted or beach aryl group of C 6 ~ C 60 ring, A substituted or unsubstituted C 6 to C 60 diarylamino group, a substituted or unsubstituted C 3 to C 60 heteroarylamino group, a substituted or unsubstituted C 2 to C 60 diheteroarylamino group, a C 7 ~ C 60 when the aryl group, a substituted or unsubstituted C 3 ~ C 60 heteroaryl group, a substituted or unsubstituted C 3 ~ C 60 of the ring A substituted or unsubstituted C 1 to C 60 halogenoalkyl group, a substituted or unsubstituted C 1 to C 60 heterocycloalkyl group, a substituted or unsubstituted C 3 to C 60 alkylsilyl group, a substituted or unsubstituted C 1 to C 60 alkyl group, A substituted C 3 to C 60 arylsilyl group, and a substituted or unsubstituted C 1 to C 60 heteroarylsilyl group;

p, q, r, s 및 t 는 각각 독립적으로 0 내지 4 사이의 정수이다.p, q, r, s and t are each independently an integer of 0 to 4;

본 발명에 따르면, 상기 Ar1 및 Ar2 중 하나 이상은 하기 화학식 2a인 것을 특징으로 한다.According to the present invention, at least one of Ar 1 and Ar 2 is represented by the following formula (2a).

[화학식 2a](2a)

Figure pat00007
Figure pat00007

본 발명에 따르면, 상기 Ar1 및 Ar2 중 하나 이상은 하기 화학식 3a 또는 화학식 3b인 것을 특징으로 한다.According to the present invention, at least one of Ar 1 and Ar 2 is represented by the following general formula (3a) or (3b).

[화학식 3a][Chemical Formula 3]

Figure pat00008
Figure pat00008

[화학식 3b](3b)

Figure pat00009
Figure pat00009

본 발명에 따르면, 상기 A 및 B로 선택되는 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기는, 각각 독립적으로 치환 혹은 비치환된 페닐, 치환 혹은 비치환된 비페닐, 치환 혹은 비치환된 나프틸, 치환 혹은 비치환된 플루오레닐, 치환 혹은 비치환된 페난트레닐, 치환 혹은 비치환된 피리딘, 치환 혹은 비치환된 피리미딘, 치환 혹은 비치환의 피리다진, 치환 혹은 비치환의 피라진, 치환 혹은 비치환된 트리아진, 치환 혹은 비치환된 퀴놀린, 치환 혹은 비치환된 이소퀴놀린, 치환 혹은 비치환의 퀴녹살린, 치환 혹은 비치환된 카바졸, 및 치환 혹은 비치환의 페난트롤린로 이루어진 군에서 선택되며, 상기 치환에 사용되는 치환기 각각은 비치환된 C1~C5의 알킬기 또는 할로겐 원소로 치환된 C1~C5의 알킬기인 것을 특징으로 한다.According to the present invention, the substituted or unsubstituted C 6 to C 60 aryl group and the substituted or unsubstituted C 3 to C 60 heteroaryl group selected as A and B are each independently substituted or unsubstituted phenyl , Substituted or unsubstituted biphenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted phenanthrenyl, substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine, Substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted triazine, substituted or unsubstituted quinoline, substituted or unsubstituted quinoline, substituted or unsubstituted quinoxaline, substituted or unsubstituted carbazole , And a substituted or unsubstituted phenanthroline, and each substituent used in the substitution is a C 1 -C 5 alkyl group or a C 1 -C 5 alkyl group substituted with a halogen element .

본 발명에 따르면, 상기 R1, R4, R9 및 R10로 선택되는 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기는, 각각 독립적으로 치환 혹은 비치환된 페닐, 치환 혹은 비치환된 비페닐, 치환 혹은 비치환된 나프틸, 치환 혹은 비치환된 안트라세닐, 치환 혹은 비치환된 페난트레닐, 치환 혹은 비치환된 플루오레닐, 치환 혹은 비치환된 플루오란테닐, 치환 혹은 비치환된 피리딘, 치환 혹은 비치환된 피리미딘, 치환 혹은 비치환된 트리아진, 치환 혹은 비치환된 피리다진, 치환 혹은 비치환된 피라진, 치환 혹은 비치환된 벤즈이미다졸, 치환 혹은 비치환된 퀴놀린, 치환 혹은 비치환된 이소퀴놀린, 및 치환 혹은 비치환된 카바졸로 이루어진 군에서 선택가능하며, 상기 치환에 사용되는 치환기 각각은 C1~C5의 알킬기 또는 할로겐 원소로 치환된 C1~C5의 알킬기인 것을 특징으로 한다.According to the present invention, R 1 , R 4 , R 9 And substituted is selected as R 10, or unsubstituted C 6 ~ C 60 aryl group, and a group heteroaryl substituted or unsubstituted C 3 ~ C 60, each independently represent a substituted or unsubstituted phenyl, substituted or unsubstituted ring Biphenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted anthracenyl, substituted or unsubstituted phenanthrenyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted fluoranthenyl, substituted or unsubstituted Substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, Substituted or unsubstituted isoquinolines, and substituted or unsubstituted carbazoles, and each of the substituents used for the substitution is selected from the group consisting of a C 1 to C 5 alkyl group or a C 1 to C 5 substituted egg Characterized in that group.

본 발명에 따르면, (i) 양극, (ii) 음극, 및 (iii) 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 전계 발광 소자로서, 상기 유기물층 중 하나 이상은 제1항 내지 제5항 중 어느 한 항에 따른 화합물을 포함하는 것을 특징으로 하는 유기 전계 발광 소자를 제공한다.According to the present invention, there is provided an organic electroluminescent device comprising (i) an anode, (ii) a cathode, and (iii) one or more organic layers sandwiched between the anode and the cathode, The organic electroluminescent device includes the compound according to any one of claims 1 to 5.

본 발명에 따르면, 상기 유기 전계 발광 소자는 상기 상술한 본 발명에 따른 화합물을 발광층에 포함하는 것을 특징으로 한다.According to the present invention, the organic electroluminescent device includes the above-described compound according to the present invention in a light emitting layer.

본 발명에 따른 화학식 1로 표시되는 화합물은 휘도, 전력효율, 내열성, 정공수송 성능 및 정공주입 성능이 우수하고, 색순도 및 발광효율의 증가를 나타낼 수 있으므로, 유기 전계 발광 소자의 정공 주입층, 정공 수송층 및 발광층 중 하나 이상에 적용할 수 있다. The compound represented by the formula (1) according to the present invention is excellent in luminance, power efficiency, heat resistance, hole transporting ability and hole injection performance, and can exhibit an increase in color purity and luminous efficiency, A light-emitting layer, a light-emitting layer, a light-emitting layer, and a light-emitting layer.

본 발명에 다른 화학식 1로 표시되는 화합물을 포함하는 유기 전계 발광 소자를 낮은 구동 전압과 높은 효율을 나타내며, 이에 따라 유기 발광 소자 패널에서 성능 극대화 및 수명 향상에 우수한 효과를 갖는다.The organic electroluminescent device including the compound represented by Formula 1 according to the present invention exhibits low driving voltage and high efficiency and thus has an excellent effect in maximizing the performance and lifetime of the OLED panel.

도 1은 본 발명의 일 실시예에 따른 유기 EL 소자의 개략적인 단면도이다.1 is a schematic cross-sectional view of an organic EL device according to an embodiment of the present invention.

상기 상술한 목적을 달성하기 위한 본 발명은 아크리딘 구조를 포함하는 신규한 화합물 및 이를 이용한 유기 전계 발광 소자인 것을 특징으로 한다. 더욱 상세하게는 이를 다층 구조의 유기 전계 발광소자의 유기 발광층(EML)의 도판트(dopant)로 사용함으로써 발광 효율 및 휘도가 향상되고 수명이 연장될 뿐만 아니라 열 안정성이 우수한 청색 유기 전계 발광 소자를 제공할 수 있다. 이하 본 발명의 구성을 더욱 상세하게 살펴보도록 한다.In order to accomplish the above object, the present invention is a novel compound containing an acridine structure and an organic electroluminescent device using the same. More particularly, the present invention relates to a blue organic electroluminescent device which is improved in luminous efficiency and luminance, prolongs its lifetime and is excellent in thermal stability by using it as a dopant of an organic light emitting layer (EML) of a multilayer organic electroluminescent device . Hereinafter, the configuration of the present invention will be described in more detail.

본 발명은 하기 화학식 1로 표시되는 화합물을 제공한다. The present invention provides a compound represented by the following formula (1).

[화학식 1][Formula 1]

Figure pat00010
Figure pat00010

상기 화학식 1에서, In Formula 1,

A 및 B는 각각 독립적으로 단일결합, 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기로 이루어진 군에서 선택되고;A and B are each independently selected from a single bond, a substituted or an aryl group of a beach C 6 ~ C 60 ring, and a substituted or unsubstituted C 3 ~ C 60 heteroaryl group consisting of a ring;

n은 0 또는 1이고, 단 n이 0 일때 상기 A 및 B가 동시에 단일결합인 경우를 제외하고;n is 0 or 1 except when A and B are simultaneously a single bond when n is 0;

Ar1 및 Ar2는 각각 독립적으로 하기 화학식 2 내지 화학식 4로 이루어진 군에서 선택되나, 상기 Ar1 및 Ar2가 동시에 화학식 4인 경우를 제외하고;Ar 1 and Ar 2 are each independently selected from the group consisting of the following formulas (2) to (4) except that Ar 1 and Ar 2 are simultaneously represented by formula (4);

[화학식 2](2)

Figure pat00011
Figure pat00011

[화학식 3](3)

Figure pat00012
Figure pat00012

[화학식 4][Formula 4]

Figure pat00013
Figure pat00013

R1 내지 R10은 각각 독립적으로 치환 혹은 비치환된 C1~C60의 알킬기, 치환 혹은 비치환된 C2~C60의 알케닐기, 치환 혹은 비치환된 C2~C60의 알키닐기, 치환 혹은 비치환된 C6~C60의 아릴기, 치환 혹은 비치환된 C3~C60의 헤테로아릴기, 치환 혹은 비치환된 C1~C60의 알콕시기, 치환 혹은 비치환된 C6~C60의 아릴옥시기, 치환 혹은 비치환된 C7~C60의 아릴알킬기, 치환 혹은 비치환된 C3~C60의 헤테로아릴알킬기, 치환 혹은 비치환된 C3~C60의 시클로알킬기, 치환 혹은 비치환된 C1~C60의 할로겐알킬기, 치환 혹은 비치환된 C1~C60의 헤테로시클로알킬기, 치환 혹은 비치환된 C3~C60 의 알킬실릴기, 치환 혹은 비치환된 C3~C60의 아릴실릴기, 및 치환 혹은 비치환된 C1~C60의 헤테로아릴실릴기로 이루어진 군에서 선택되고; Each of R 1 to R 10 independently represents a substituted or unsubstituted C 1 to C 60 alkyl group, a substituted or unsubstituted C 2 to C 60 alkenyl group, a substituted or unsubstituted C 2 to C 60 alkynyl group, A substituted or unsubstituted C 6 to C 60 aryl group, a substituted or unsubstituted C 3 to C 60 heteroaryl group, a substituted or unsubstituted C 1 to C 60 alkoxy group, a substituted or unsubstituted C 6 to C 60 aryl group, ~ C 60 of the aryloxy group, a substituted or unsubstituted C 7 ~ C 60 aryl group, a substituted or unsubstituted C 3 ~ C 60 heteroaryl group, a substituted or unsubstituted C 3 ~ cycloalkyl group of C 60 of the , A substituted or unsubstituted C 1 to C 60 halogenalkyl group, a substituted or unsubstituted C 1 to C 60 heterocycloalkyl group, a substituted or unsubstituted C 3 to C 60 alkylsilyl group, a substituted or unsubstituted A C 3 to C 60 arylsilyl group, and a substituted or unsubstituted C 1 to C 60 heteroarylsilyl group;

R1 내지 R8은 각각 인접하는 치환기와 융합(fused)되거나 고리를 형성할 수 있고;R 1 to R 8 may each be fused or may form a ring with adjacent substituents;

X1 내지 X5는 각각 독립적으로 수소, 중수소, 할로겐, 아미노기, 니트로기, 니트릴기, 치환 혹은 비치환된 C1~C60의 알킬기, 치환 혹은 비치환된 C2~C60의 알케닐기, 치환 혹은 비치환된 C2~C60의 알키닐기, 치환 혹은 비치환된 C6~C60의 아릴기, 치환 혹은 비치환된 C3~C60의 헤테로아릴기, 치환 혹은 비치환된 C1~C60의 알콕시기, 치환 혹은 비치환된 C6~C60의 아릴옥시기, 치환 혹은 비치환된 C6~C60의 알킬아미노기, 치환 혹은 비치환된 C6~C60의 아릴아미노기, 치환 혹은 비치환된 C6~C60의 디아릴아미노기, 치환 혹은 비치환된 C3~C60의 헤테로아릴아미노기, 치환 혹은 비치환된 C2~C60의 디헤테로아릴아미노기, 치환 혹은 비치환된 C7~C60의 아릴알킬기, 치환 혹은 비치환된 C3~C60의 헤테로아릴알킬기, 치환 혹은 비치환된 C3~C60의 시클로알킬기, 치환 혹은 비치환된 C1~C60의 할로겐알킬기, 치환 혹은 비치환된 C1~C60의 헤테로시클로알킬기, 치환 혹은 비치환된 C3~C60 의 알킬실릴기, 치환 혹은 비치환된 C3~C60의 아릴실릴기, 및 치환 혹은 비치환된 C1~C60의 헤테로아릴실릴기로 이루어진 군에서 선택되고;X 1 to X 5 each independently represent hydrogen, deuterium, a halogen, an amino group, a nitro group, a nitrile group, a substituted or unsubstituted C 1 to C 60 alkyl group, a substituted or unsubstituted C 2 to C 60 alkenyl group, A substituted or unsubstituted C 2 to C 60 alkynyl group, a substituted or unsubstituted C 6 to C 60 aryl group, a substituted or unsubstituted C 3 to C 60 heteroaryl group, a substituted or unsubstituted C 1 to C 60 heteroaryl group, ~ C 60 alkoxy group, a substituted or unsubstituted C 6 ~ C 60 of the aryloxy group, a substituted or unsubstituted C 6 ~ C 60 alkyl group, a substituted or beach aryl group of C 6 ~ C 60 ring, A substituted or unsubstituted C 6 to C 60 diarylamino group, a substituted or unsubstituted C 3 to C 60 heteroarylamino group, a substituted or unsubstituted C 2 to C 60 diheteroarylamino group, a C 7 ~ C 60 when the aryl group, a substituted or unsubstituted C 3 ~ C 60 heteroaryl group, a substituted or unsubstituted C 3 ~ C 60 of the ring A substituted or unsubstituted C 1 to C 60 halogenoalkyl group, a substituted or unsubstituted C 1 to C 60 heterocycloalkyl group, a substituted or unsubstituted C 3 to C 60 alkylsilyl group, a substituted or unsubstituted C 1 to C 60 alkyl group, A substituted C 3 to C 60 arylsilyl group, and a substituted or unsubstituted C 1 to C 60 heteroarylsilyl group;

p, q, r, s 및 t 는 각각 독립적으로 0 내지 4 사이의 정수이다.
p, q, r, s and t are each independently an integer of 0 to 4;

본 발명의 화학식 1 로 표시되는 화합물은 다음과 같은 화학식으로 나타낼 수 있다. The compound represented by formula (1) of the present invention can be represented by the following formula.

Figure pat00014
Figure pat00014

Figure pat00015

Figure pat00015

상기 식에서, R1 내지 R10은 상기 화학식 1에서의 정의와 동일하고, R1' 내지 R8'은 R1 내지 R8의 정의와 동일하다.
In the above formulas, R 1 to R 10 are the same as defined in the above formula (1), and R 1 'to R 8 ' are the same as R 1 to R 8 .

한편 더욱 구체적으로 본 발명의 화학식 1로 표시되는 상기 화합물에서, R1 내지 R8, R1' 내지 R8', R9 및 R10는 서로 같거나 상이하며, 각각 독립적으로 하기 기재된 구조의 치환기에서 선택될 수 있다. 그러나 하기 예시된 치환기로만 한정되는 것은 아니다.R 1 to R 8 , R 1 'to R 8 ', R 9 and R 10 are the same as or different from each other, and each independently represents a substituent ≪ / RTI > However, it is not limited to the substituents exemplified below.

Figure pat00016

Figure pat00016

아래 화합물들은 본 발명의 화학식 1로 표시되는 화합물의 대표적인 예들이나, 본 발명의 화학식 1로 표시되는 화합물이 이에 한정되는 것은 아니다.
The following compounds are representative examples of the compound represented by the formula (1) of the present invention, but the compounds represented by the formula (1) of the present invention are not limited thereto.

Figure pat00017
Figure pat00017

Figure pat00018
Figure pat00018

Figure pat00019
Figure pat00019

Figure pat00020
Figure pat00020

Figure pat00021
Figure pat00021

Figure pat00022
Figure pat00022

Figure pat00023
Figure pat00023

Figure pat00024
Figure pat00024

Figure pat00025
Figure pat00025

Figure pat00026
Figure pat00026

Figure pat00027
Figure pat00027

본 발명의 화학식 1 로 표시되는 화합물은 일반적인 합성방법에 따라 합성될 수 있으며, 본 발명의 화합물에 대한 상세한 합성 과정은 후술하는 합성 예에서 구체적으로 기술하도록 한다.
The compound represented by the formula (1) of the present invention can be synthesized according to a general synthesis method, and the detailed synthesis process of the compound of the present invention will be described concretely in a synthesis example described later.

보다 바람직하게는, 본 발명에 따른 화합물은 상기 화학식 1로 표시되는 화합물에서 상기 Ar1 및 Ar2 중 어느 하나 이상은 하기 화학식 2a인 것을 특징으로 한다.More preferably, the compound according to the present invention is a compound represented by the general formula (1), wherein at least one of Ar 1 and Ar 2 is represented by the following general formula (2a).

[화학식 2a](2a)

Figure pat00028
Figure pat00028

또한 보다 바람직하게는, 상기 화학식 1로 표시되는 화합물에서 상기 Ar1 및 Ar2 중 어느 하나 이상은 하기 화학식 3a 또는 화학식 3b인 것을 특징으로 한다.More preferably, at least one of Ar 1 and Ar 2 in the compound represented by Formula 1 is represented by Formula 3a or Formula 3b.

[화학식 3a][Chemical Formula 3]

Figure pat00029
Figure pat00029

[화학식 3b](3b)

Figure pat00030

Figure pat00030

또한 보다 바람직하게는, 상기 화학식 1로 표시되는 화합물에서 상기 A 및 B로 선택되는 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기는, 각각 독립적으로 치환 혹은 비치환된 페닐, 치환 혹은 비치환된 비페닐, 치환 혹은 비치환된 나프틸, 치환 혹은 비치환된 플루오레닐, 치환 혹은 비치환된 페난트레닐, 치환 혹은 비치환된 피리딘, 치환 혹은 비치환된 피리미딘, 치환 혹은 비치환의 피리다진, 치환 혹은 비치환의 피라진, 치환 혹은 비치환된 트리아진, 치환 혹은 비치환된 퀴놀린, 치환 혹은 비치환된 이소퀴놀린, 치환 혹은 비치환의 퀴녹살린, 치환 혹은 비치환된 카바졸, 및 치환 혹은 비치환의 페난트롤린로 이루어진 군에서 선택되며, 상기 치환에 사용되는 치환기 각각은 비치환된 C1~C5의 알킬기 또는 할로겐 원소로 치환된 C1~C5의 알킬기인 것을 특징으로 한다.More preferably, the substituted or unsubstituted C 6 to C 60 aryl group and the substituted or unsubstituted C 3 to C 60 heteroaryl group selected from A and B in the compound represented by the general formula (1) Substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted phenanthrenyl, substituted or unsubstituted pyridine , Substituted or unsubstituted pyrimidine, substituted or unsubstituted pyridazine, substituted or unsubstituted pyrazine, substituted or unsubstituted triazine, substituted or unsubstituted quinoline, substituted or unsubstituted isoquinoline, substituted or unsubstituted quinox Substituted or unsubstituted carbazoles, and substituted or unsubstituted phenanthrolines, wherein each substituent used in the substitution is selected from the group consisting of an unsubstituted C 1 -C 5 alkyl group or a And is a C 1 - C 5 alkyl group substituted with a halogen atom.

또한 보다 바람직하게는, 상기 화학식 1로 표시되는 화합물에서 상기 R1, R4, R9 및 R10로 선택되는 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기는, 각각 독립적으로 치환 혹은 비치환된 페닐, 치환 혹은 비치환된 비페닐, 치환 혹은 비치환된 나프틸, 치환 혹은 비치환된 안트라세닐, 치환 혹은 비치환된 페난트레닐, 치환 혹은 비치환된 플루오레닐, 치환 혹은 비치환된 플루오란테닐, 치환 혹은 비치환된 피리딘, 치환 혹은 비치환된 피리미딘, 치환 혹은 비치환된 트리아진, 치환 혹은 비치환된 피리다진, 치환 혹은 비치환된 피라진, 치환 혹은 비치환된 벤즈이미다졸, 치환 혹은 비치환된 퀴놀린, 치환 혹은 비치환된 이소퀴놀린, 및 치환 혹은 비치환된 카바졸로 이루어진 군에서 선택가능하며, 상기 치환에 사용되는 치환기 각각은 C1~C5의 알킬기 또는 할로겐 원소로 치환된 C1~C5의 알킬기인 것을 특징으로 한다.
More preferably, in the compound represented by the general formula (1), R 1 , R 4 , R 9 And substituted is selected as R 10, or unsubstituted C 6 ~ C 60 aryl group, and a group heteroaryl substituted or unsubstituted C 3 ~ C 60, each independently represent a substituted or unsubstituted phenyl, substituted or unsubstituted ring Biphenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted anthracenyl, substituted or unsubstituted phenanthrenyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted fluoranthenyl, substituted or unsubstituted Substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, Substituted or unsubstituted isoquinolines, and substituted or unsubstituted carbazoles, and each of the substituents used for the substitution is selected from the group consisting of a C 1 to C 5 alkyl group or a C 1 to C 5 substituted egg Characterized in that group.

본 발명의 다른 측면은, 구체적으로는 화학식 1 표시되는 화합물, 보다 구체적으로 상기에서 화학식 1 내지 화학식 4로 상술한 화합물을 포함하는 유기 전계 발광 소자에 관한 것이다.Another aspect of the present invention relates to an organic electroluminescent device including a compound represented by Formula 1, more specifically, a compound described above in Formula 1 to Formula 4 above.

구체적으로, 본 발명은 양극(anode), 음극(cathode), 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물 층을 포함하는 유기 발광 소자로서, 상기 유기물 층 중 적어도 하나 이상은 상기 화학식 1로 표시되는 화합물을 포함하는 유기 전계 발광 소자를 제공한다.
More specifically, the present invention relates to an organic light emitting device comprising an anode, a cathode, and at least one organic layer interposed between the anode and the cathode, An organic electroluminescent device comprising a compound represented by the general formula (1).

*보다 바람직하게는, 상기 유기 전계 발광 소자는 상기 화학식 1에서 Ar1 및 Ar2 중 어느 하나 이상은 상기 화학식 2a인 화합물을 포함하는 것을 특징으로 한다.More preferably, the organic electroluminescent device is characterized in that at least one of Ar 1 and Ar 2 in Formula 1 includes the compound of Formula 2a.

또한 보다 바람직하게는, 상기 유기 전계 발광 소자는 상기 화학식 1에서 Ar1 및 Ar2 중 어느 하나 이상은 상기 화학식 3a 또는 화학식 3b인 화합물을 포함하는 것을 특징으로 한다.More preferably, the organic electroluminescent device is characterized in that at least one of Ar 1 and Ar 2 in Formula 1 includes the compound of Formula 3a or Formula 3b.

또한 보다 바람직하게는, 상기 유기 전계 발광 소자는 상기 화학식 1 에서 A 및 B로 선택되는 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기는, 각각 독립적으로 치환 혹은 비치환된 페닐, 치환 혹은 비치환된 비페닐, 치환 혹은 비치환된 나프틸, 치환 혹은 비치환된 플루오레닐, 치환 혹은 비치환된 페난트레닐, 치환 혹은 비치환된 피리딘, 치환 혹은 비치환된 피리미딘, 치환 혹은 비치환의 피리다진, 치환 혹은 비치환의 피라진, 치환 혹은 비치환된 트리아진, 치환 혹은 비치환된 퀴놀린, 치환 혹은 비치환된 이소퀴놀린, 치환 혹은 비치환의 퀴녹살린, 치환 혹은 비치환된 카바졸, 및 치환 혹은 비치환의 페난트롤린로 이루어진 군에서 선택되며, 상기 치환에 사용되는 치환기 각각은 비치환된 C1~C5의 알킬기 또는 할로겐 원소로 치환된 C1~C5의 알킬기인 화합물을 포함하는 것을 특징으로 한다.More preferably, the organic electroluminescent device further comprises a substituted or unsubstituted C 6 to C 60 aryl group and a substituted or unsubstituted C 3 to C 60 heteroaryl group selected from A and B in the above formula Substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted phenanthrenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted naphthyl, Substituted or unsubstituted pyrimidines, substituted or unsubstituted pyridazines, substituted or unsubstituted pyrazines, substituted or unsubstituted triazines, substituted or unsubstituted quinolines, substituted or unsubstituted isoquinolines, substituted or unsubstituted pyrazines, substituted or unsubstituted pyrazines, quinoxaline, a substituted or unsubstituted carbazole, and a substituted or unsubstituted, is selected from the group consisting of phenanthroline, an alkyl group of each substituent used in the substituted is unsubstituted C 1 ~ C 5 ring again It characterized in that it comprises a C alkyl group of 1 ~ C 5 substituted with a halogen atom.

또한 보다 바람직하게는, 상기 유기 전계 발광 소자는 상기 화학식 1에서 R1, R4, R9 및 R10로 선택되는 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기는, 각각 독립적으로 치환 혹은 비치환된 페닐, 치환 혹은 비치환된 비페닐, 치환 혹은 비치환된 나프틸, 치환 혹은 비치환된 안트라세닐, 치환 혹은 비치환된 페난트레닐, 치환 혹은 비치환된 플루오레닐, 치환 혹은 비치환된 플루오란테닐, 치환 혹은 비치환된 피리딘, 치환 혹은 비치환된 피리미딘, 치환 혹은 비치환된 트리아진, 치환 혹은 비치환된 피리다진, 치환 혹은 비치환된 피라진, 치환 혹은 비치환된 벤즈이미다졸, 치환 혹은 비치환된 퀴놀린, 치환 혹은 비치환된 이소퀴놀린, 및 치환 혹은 비치환된 카바졸로 이루어진 군에서 선택가능하며, 상기 치환에 사용되는 치환기 각각은 C1~C5의 알킬기 또는 할로겐 원소로 치환된 C1~C5의 알킬기인 화합물을 포함하는 것을 특징으로 한다.More preferably, the organic electroluminescent device is a compound represented by formula (1) wherein R 1 , R 4 , R 9 And substituted is selected as R 10, or unsubstituted C 6 ~ C 60 aryl group, and a group heteroaryl substituted or unsubstituted C 3 ~ C 60, each independently represent a substituted or unsubstituted phenyl, substituted or unsubstituted ring Biphenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted anthracenyl, substituted or unsubstituted phenanthrenyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted fluoranthenyl, substituted or unsubstituted Substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, Substituted or unsubstituted isoquinolines, and substituted or unsubstituted carbazoles, and each of the substituents used for the substitution is selected from the group consisting of a C 1 to C 5 alkyl group or a C 1 to C 5 substituted egg It characterized by including the resulting compound.

이때, 상기 유기 전계 발광 소자는 상기 화학식 1 로 표시되는 화합물은 단일 종류 또는 이종의 두 가지 종류 이상의 화합물이 포함될 수 있다.In this case, the organic electroluminescent device may include two or more compounds of the same or different types.

본 발명의 상기 화학식 1 로 표시되는 화합물을 포함하는 유기물 층은 정공 주입층(103), 정공 수송층(104), 전자 주입층(108), 전자 수송층(107) 및 발광층(105) 중 어느 하나 이상일 수 있다. 이 경우 유기 전계 발광 소자는 정공 주입 능력, 전자 수송 능력, 전자 주입 능력을 극대화할 수 있다. 또한 유기 전계 발광 소자의 발광층 재료로 사용됨으로써, 보다 향상된 효율, 구동 특성 및 수명을 제공할 수 있다(도 1 참조).The organic material layer containing the compound represented by Formula 1 of the present invention may be any one or more of the hole injection layer 103, the hole transport layer 104, the electron injection layer 108, the electron transport layer 107, . In this case, the organic electroluminescent device can maximize the hole injecting ability, the electron transporting ability, and the electron injecting ability. Further, by using it as a light emitting layer material of an organic electroluminescent device, it is possible to provide a further improved efficiency, drive characteristics and lifetime (see FIG. 1).

보다 바람직하게는 상기 상술한 화합물을 포함하는 유기물층은 발광층으로서, 상기 화합물을 도판트로 포함하는 것을 특징으로 하는 유기 전계 발광 소자인 것을 특징으로 한다.More preferably, the organic compound layer containing the above-mentioned compound is an organic electroluminescent device characterized by containing the compound as a dopant as a light emitting layer.

본 발명에서 발광층은 형광 게스트 재료를 포함할 수 있다. 바람직하게는, 상기 화학식 1로 표시되는 화합물은 청색, 녹색 및/또는 적색의 인광 호스트, 형광 호스트, 정공수송 물질 및/또는 정공전달, 전자수송 물질 및/또는 전자전달 물질로서 유기 발광 소자에 포함될 수 있다. In the present invention, the light emitting layer may comprise a fluorescent guest material. Preferably, the compound represented by Formula 1 is included in the organic light emitting device as a blue, green and / or red phosphorescent host, fluorescent host, hole transport material and / or hole transport, electron transport material and / .

본 발명에 따른 유기 전계 발광 소자 구조의 비제한적인 예를 들면, 기판, 양극, 정공 주입층, 정공 수송층, 발광층, 전자 수송층 및 음극이 순차적으로 적층된 것일 수 있다. 이때 상기 발광층, 정공 주입층, 정공 수송층 중 하나 이상은 상기 화학식 1로 표시되는 화합물을 포함할 수 있다. 상기 전자 수송층 위에는 전자 주입층이 위치할 수도 있다.As a non-limiting example of the organic electroluminescent device structure according to the present invention, a substrate, an anode, a hole injection layer, a hole transport layer, a light emitting layer, an electron transport layer and a cathode may be sequentially stacked. At least one of the light emitting layer, the hole injecting layer, and the hole transporting layer may include the compound represented by Formula 1. An electron injection layer may be disposed on the electron transport layer.

또한, 본 발명에 따른 유기 발광 소자는 전술한 바와 같이 양극, 1층 이상의 유기물 층 및 음극이 순차적으로 적층된 구조 뿐만 아니라, 전극과 유기물 층 계면에 절연층 또는 접착층이 삽입될 수도 있다. In addition, the organic light emitting device according to the present invention may have an insulating layer or an adhesive layer interposed between the electrode and the organic material layer as well as the structure in which the anode, one or more organic layers and the cathode are sequentially stacked, as described above.

본 발명의 유기 발광 소자에 있어서, 상기 화학식 1의 화합물을 포함하는 상기 유기물 층은 진공 증착법이나 용액 도포법에 의하여 형성될 수 있다. 상기 용액 도포의 예로는 스핀 코팅, 딥 코팅, 닥터 블레이딩, 잉크젯 프린팅 또는 열 전사법 등이 있으나, 이들에만 한정되지 않는다. In the organic light emitting device of the present invention, the organic material layer containing the compound of Formula 1 may be formed by a vacuum evaporation method or a solution coating method. Examples of the application of the solution include, but are not limited to, spin coating, dip coating, doctor blading, inkjet printing, or thermal transfer.

본 발명에 따른 유기 전계 발광 소자는, 유기물층 중 1층 이상을 상기 화학식 1로 표시되는 화합물을 포함하도록 형성하는 것을 제외하고는, 당 기술 분야에 알려져 있는 통상적인 재료 및 방법을 이용하여 유기물층 및 전극을 형성하여 제조될 수 있다.The organic electroluminescent device according to the present invention can be manufactured by using a conventional material and method known in the art, except that at least one layer of the organic material layer includes the compound represented by the above formula (1) ≪ / RTI >

예컨데, 기판으로는 실리콘 웨이퍼, 석영, 유리판, 금속판, 플라스틱 필름이나 시트 등이 사용될 수 있다.For example, the substrate may be a silicon wafer, quartz, a glass plate, a metal plate, a plastic film, or a sheet.

양극 물질로는 바나듐, 크롬, 구리, 아연, 금과 같은 금속 또는 이들의 합금; 아연산화물, 인듐산화물, 인듐 주석 산화물(ITO), 인듐 아연 산화물(IZO)과 같은 금속 산화물; ZnO:Al 또는 SnO2:Sb와 같은 금속과 산화물의 조합물; 폴리티오펜, 폴리(3-메틸티오펜), 폴리[3,4-(에틸렌-1,2-디옥시)티오펜] (PEDT), 폴리피롤 및 폴리아닐린과 같은 전도성 고분자; 또는 카본블랙 등이 있으나, 이들에만 한정 되는 것은 아니다.Examples of the positive electrode material include metals such as vanadium, chromium, copper, zinc, and gold, or alloys thereof; Metal oxides such as zinc oxide, indium oxide, indium tin oxide (ITO), and indium zinc oxide (IZO); ZnO: Al or SnO 2: a combination of metal and oxides such as Sb; Conductive polymers such as polythiophene, poly (3-methylthiophene), poly [3,4- (ethylene-1,2-dioxy) thiophene] (PEDT), polypyrrole and polyaniline; Or carbon black, but are not limited thereto.

음극 물질로는 마그네슘, 칼슘, 나트륨, 칼륨, 타이타늄, 인듐, 이트륨, 리튬, 가돌리늄, 알루미늄, 은, 주석 또는 납과 같은 금속 또는 이들의 합금; LiF/Al 또는 LiO2/Al과 같은 다층 구조 물질 등이 있으나, 이들에만 한정되는 것은 아니다.Examples of the negative electrode material include metals such as magnesium, calcium, sodium, potassium, titanium, indium, yttrium, lithium, gadolinium, aluminum, silver, tin or lead or alloys thereof; Layer structure materials such as LiF / Al or LiO 2 / Al, but are not limited thereto.

상기 정공 주입층, 정공 수송층 및 전자 주입층은 특별히 한정되는 것은 아니며, 당해 기술 분야에서 알려진 통상의 물질이 사용될 수 있다.
The hole injecting layer, the hole transporting layer, and the electron injecting layer are not particularly limited, and conventional materials known in the art can be used.

이하에서는 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 다만, 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다 할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It should be understood, however, that these examples are for illustrative purposes only and are not to be construed as limiting the scope of the present invention.

1. One. 준비예Preparation Example A의 합성( Synthesis of A ArAr ))

1. 1. 1. 1. 준비예Preparation Example A1의 합성 Synthesis of A1

Figure pat00031
Figure pat00031

Figure pat00032
Figure pat00032

2L 둥근 플라스크에 31.4g(150mmol)의 9,9-dimethyl-9,10-dihydroacridine과 bromobenzene 23.5g (1당량), sodium tert-butoxide 42.7g(3당량), tris(dibenzylideneacetone)dipalladium) 2.55g(3 mol %), 1,1 -bis(diphenylphosphino) ferrocene 2.5g (3 mol %)을 질소 조건에서 첨가한 후 toluene 750ml 에서 over night 동안 환류 교반 하였다. 반응 종료 후 반응액을 Celite를 통해 Filter한 다음, 컬럼 크로마토그래피를 통하여 9,9-dimethyl-10-phenyl-9,10-dihydroacridine 34g (수율 80%)을 얻었다. To a 2 L round bottom flask was added 31.4 g (150 mmol) of 9,9-dimethyl-9,10-dihydroacridine and 23.5 g (1 equivalent) of bromobenzene, 42.7 g (three equivalents) of sodium tert-butoxide and 2.55 g (dibenzylideneacetone) dipalladium 2.5 mol (3 mol%) of 1,1-bis (diphenylphosphino) ferrocene was added under nitrogen atmosphere and then refluxed in 750 ml of toluene over night. After completion of the reaction, the reaction solution was filtered through Celite, and 34 g (yield 80%) of 9,9-dimethyl-10-phenyl-9,10-dihydroacridine was obtained through column chromatography.

상기에서 합성된 9,9-dimethyl-10-phenyl-9,10-dihydroacridine 34g (105mmol)과 n-bromosuccin imide 19g (1당량) 을 2L 둥근 플라스크에 500ml 사염화탄소와 함께 질소분위기 하에서 3시간 교반 하였다. 반응 종료 후 반응액을 Celite를 통해 Filter한 다음, 컬럼 크로마토그래피를 통하여 준비예 A1 화합물 2-bromo-9,9-dimethyl-10-phenyl-9,10-dihydroacridine 23g (수율 60%)을 얻었다.
34 g (105 mmol) of 9,9-dimethyl-10-phenyl-9,10-dihydroacridine synthesized above and 19 g (1 equivalent) of n-bromosuccinimide were stirred in a 2 L round flask with 500 ml of carbon tetrachloride for 3 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was filtered through a Celite column, and 23 g (yield: 60%) of 2-bromo-9,9-dimethyl-10-phenyl-9,10-dihydroacridine of Preparation Example A1 was obtained through column chromatography.

1. 2. 1. 2. 준비예Preparation Example A2의 합성 Synthesis of A2

Figure pat00033
Figure pat00033

Figure pat00034
Figure pat00034

Figure pat00035
Figure pat00035

Figure pat00036
Figure pat00036

2L 둥근바닥 플라스크에 60.2g(200mmol)의 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-ol, toluene 30ml, pyridine 79.0g(5당량)을 넣고 0℃로 낮춘 상태에서 trifluoromethanesulfonic anhydride 62.0g(1.1당량)을 넣고 30분간 두었다. 그 후 실온에서 4시간 교반한 후 물을 넣고 반응을 종료했다. 반응액을 분리한 후 얻어진 유기층은 물, 5%염산으로 세척하고 무수 황산마그네슘으로 건조했다. 상기에서 얻어진 유기층으로부터 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl sulfochloridate을 71.8g (180mmol)(수율: 90%)얻었다. To a 2 L round bottom flask was added 60.2 g (200 mmol) of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-ol, 30 ml of toluene and 79.0 g (5 eq.) Of pyridine, 62.0 g (1.1 eq.) of anhydride was added and the mixture was allowed to stand for 30 minutes. After that, the reaction mixture was stirred at room temperature for 4 hours, and water was added thereto to terminate the reaction. After the reaction solution was separated, the obtained organic layer was washed with water, 5% hydrochloric acid and dried over anhydrous magnesium sulfate. 71.8 g (180 mmol) (yield: 90%) of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl sulfochloridate was obtained from the organic layer obtained above.

상기에서 합성된 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl sulfochloridate 71.8g (180mmol), 2-acetoxy-4-bromophenylboronic acid 55.7g (1.2당량), dimethoxy ethame 1000ml, 20% disodium carbonate 85.8g(4.5당량) 을 2L 둥근 플라스크에 넣고 질소 분위기 하에서 Pd(PPh3)4 2.1g(1당량)을 첨가하고 환류조건하에서 4시간 교반했다. 실온까지 냉각 후 반응액에서 유기층을 분리하고 물로 세척후 무수 황산 마그네슘으로 건조했다. 얻어진 잔사를 컬럼 크로마토그래피를 통하여 정제하고 1-(5-bromo-2-(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)phenyl)ethanone 70.1g (수율 81%)을 얻었다.71.8 g (180 mmol) of the 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl sulfochloridate synthesized above, 55.7 g (1.2 equivalent) of 2-acetoxy-4-bromophenylboronic acid, 85.8 g (4.5 eq.) of disodium carbonate were placed in a 2 L round-bottomed flask and 2.1 g (1 equivalent) of Pd (PPh3) 4 was added under nitrogen atmosphere and the mixture was stirred under refluxing conditions for 4 hours. After cooling to room temperature, the organic layer was separated from the reaction solution, washed with water, and dried over anhydrous magnesium sulfate. The resulting residue was purified by column chromatography to obtain 70.1 g (yield 81%) of 1- (5-bromo-2- (9,9-dimethyl-10-phenyl-9,10-dihydroacridin- ≪ / RTI >

상기에서 합성된 1-(5-bromo-2-(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)phenyl) ethanone 70.1g (146mmol)에 THF 500ml를 질소 치환한 2L 플라스크에 넣고 50℃까지 승온했다. 이 반응기에 methylmagnesium bromide 24.3g(1.4당량)에 toluene과 THF를 3:1의 비율로 섞은 용액 250ml를 질소 분위기 하에서 1시간 동안 천천히 섞어준 후 50℃에서 3시간 교반했다. 실온까지 냉각 후 반응액에 물을 넣어 반응을 종료하고 세척 후 무수 황산 마그네슘으로 건조했다. 2-(5-bromo-2-(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)phenyl)propan-2-ol 58.0g (수율 80%)을 얻었다.(146 mmol) of 1- (5-bromo-2- (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl) phenyl) ethanone synthesized above was dissolved in THF (500 ml) And the temperature was raised to 50 캜. To this reactor, 250 ml of a solution of methylmagnesium bromide (24.3 g, 1.4 equivalents) in which toluene and THF were mixed at a ratio of 3: 1 was slowly mixed in an atmosphere of nitrogen for 1 hour and then stirred at 50 ° C for 3 hours. After cooling to room temperature, water was added to the reaction solution to complete the reaction, followed by washing and drying with anhydrous magnesium sulfate. 58.0 g (yield 80%) of 2- (5-bromo-2- (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl) phenyl) propan-

상기에서 합성된 2-(5-bromo-2-(9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)phenyl)propan-2-ol 58.0g (117mmol), Chloroform 1000ml를 질소 치환한 2L 플라스크에 넣고 trifluoroborone diethylether 24.9g(1.5당량)을 질소 분위기 하에서 10분간 섞어주었다. 이후 50℃까지 승온하고 2시간 동안 교반 후 반응을 종료하였다. 실온까지 냉각 후 물에 세척하고 얻어진 유기층을 무수 황산 마그네슘으로 건조했다. 농축 후에 얻어진 잔사를 컬럼 크로마토그래피로 정제 후, 재결정하여 준비예 A2 화합물 9-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno[1,2-b]acridine 22.4g(수율 40%)를 얻었다.
58.0 g (117 mmol) of 2- (5-bromo-2- (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl) phenyl) propan- 24.9 g (1.5 eq.) Of trifluoroborone diethylether were added to a nitrogen-substituted 2 L flask, and the mixture was stirred for 10 minutes under a nitrogen atmosphere. Thereafter, the temperature was raised to 50 DEG C, and the reaction was terminated after stirring for 2 hours. After cooling to room temperature, the organic layer was washed with water, and the obtained organic layer was dried over anhydrous magnesium sulfate. The residue obtained after concentration was purified by column chromatography and recrystallized to obtain the compound of Preparation A2, 9-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro- b] acridine (yield: 40%).

1.3. 1.3. 준비예Preparation Example A3의 합성 Synthesis of A3

Figure pat00037
Figure pat00037

Figure pat00038

Figure pat00038

준비예 A2의 합성과정에서 methylmagnesium bromide 대신 phenylmagnesium bromide를 사용한 것을 제외하고는 동일한 방법으로 합성하여 준비예 A3 화합물 9-bromo-13,13-dimethyl-5,7,7-triphenyl-7,13-dihydro-5H-indeno[1,2-b]acridine를 얻었다.
Preparative Example A3 The compound 9-bromo-13,13-dimethyl-5,7,7-triphenyl-7,13-dihydro was synthesized by the same method except that phenylmagnesium bromide was used instead of methylmagnesium bromide in the synthesis of A2. -5H-indeno [1,2-b] acridine.

1.4. 1.4. 준비예Preparation Example A4의 합성 Synthesis of A4

Figure pat00039
Figure pat00039

Figure pat00040

Figure pat00040

준비예 A1의 합성과정에서 bromobenzene 대신 2-bromonaphthalene를 사용하는 것을 제외하고는 동일한 방법으로 합성하여 준비예 A4 화합물 2-bromo-9,9-dimethyl-10-(naphthalen-2-yl)-9,10-dihydroacridine을 얻었다.
Preparative Example Preparation Example A4 Preparation 2-bromo-9,9-dimethyl-10- (naphthalen-2-yl) -9, 2-bromo- 10-dihydroacridine.

1.5. 1.5. 준비예Preparation Example A5의 합성 Synthesis of A5

Figure pat00041
Figure pat00041

Figure pat00042
Figure pat00042

Figure pat00043
Figure pat00043

Figure pat00044

Figure pat00044

준비예 A2의 합성과정에서 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-ol 대신 9,9-dimethyl-10-(naphthalen-2-yl)-9,10-dihydroacridin-2-ol 를 사용하는 것을 제외하고는 동일한 방법으로 합성하여 준비예 A5 화합물 9-bromo-7,7,13,13-tetramethyl-5-(naphthalen-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine을 얻었다.
9,9-dimethyl-10- (naphthalen-2-yl) -9,10-dihydroacridin-2 was used in place of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin- -ol was used to prepare the compound 9-bromo-7,7,13,13-tetramethyl-5- (naphthalen-2-yl) -7,13-dihydro- indeno [1,2-b] acridine.

*1.6. 준비예 A6의 합성
* 1.6. Preparation Example A6 Synthesis

Figure pat00045
Figure pat00045

Figure pat00046

Figure pat00046

준비예 A1의 합성과정에서 bromobenzene 대신 1-bromo-4-tert-butylbenzene를 사용하는 것을 제외하고는 동일한 방법으로 합성하여 준비예 A6 화합물 2-bromo-10-(4-tert-butylphenyl)-9,9-dimethyl-9,10-dihydroacridine을 얻었다.
Preparation Example A6 Synthesis was carried out in the same manner except that 1-bromo-4-tert-butylbenzene was used instead of bromobenzene in the synthesis process A1. Preparation Example A6 Synthesis of 2-bromo-10- (4-tert-butylphenyl) 9-dimethyl-9,10-dihydroacridine.

1.7. 1.7. 준비예Preparation Example A7의 합성 Synthesis of A7

Figure pat00047
Figure pat00047

Figure pat00048
Figure pat00048

Figure pat00049
Figure pat00049

Figure pat00050

Figure pat00050

준비예 A2의 합성과정에서 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-ol 대신 10-(4-tert-butylphenyl)-9,9-dimethyl-9,10-dihydroacridin-2-ol 를 사용하는 것을 제외하고는 동일한 방법으로 합성하여 준비예 A7 화합물 9-bromo-5-(4-tert-butylphenyl)-7,7,13,13-tetramethyl-7,13-dihydro-5H-indeno[1,2b]acridine 을 얻었다.
(4-tert-butylphenyl) -9,9-dimethyl-9,10-dihydroacridin-2 was used in place of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin- -ol was used to synthesize the compound 9-bromo-5- (4-tert-butylphenyl) -7,7,13,13-tetramethyl-7,13-dihydro- indeno [l, 2b] acridine.

1.8. 1.8. 준비예Preparation Example A8의 합성 Synthesis of A8

Figure pat00051
Figure pat00051

Figure pat00052

Figure pat00052

준비예 A1의 합성 과정에서 bromobenzene 대신 4-bromobiphenyl를 사용하는 것을제외하고는 동일한 방법으로 합성하여 준비예 A8 화합물 10-(biphenyl-4-yl)-2-bromo-9,9-dimethyl-9,10-dihydroacridine을 얻었다.
Preparative Example Preparation Example A8 Synthesis of compound 10- (biphenyl-4-yl) -2-bromo-9,9-dimethyl-9,10-dibromobenzene was carried out by the same method except that 4-bromobiphenyl was used instead of bromobenzene in the synthesis of A1. 10-dihydroacridine.

1.9. 1.9. 준비예Preparation Example A9의 합성 Synthesis of A9

Figure pat00053
Figure pat00053

Figure pat00054
Figure pat00054

Figure pat00055
Figure pat00055

Figure pat00056

Figure pat00056

준비예 A2의 합성과정에서 9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-ol 대신 10-(biphenyl-4-yl)-9,9-dimethyl-9,10-dihydroacridin-2-ol를 사용하는 것을 제외하고는 동일한 방법으로 합성하여 준비예 A9 화합물 5-(biphenyl-4-yl)-9-bromo-7,7,13,13-tetramethyl-7,13-dihydro-5H-indeno[1,2-b]acridine 을 얻었다.
(Biphenyl-4-yl) -9,9-dimethyl-9,10-dihydroacridin-2 was used in place of 9,9-dimethyl-10-phenyl-9,10-dihydroacridin- -ol was used instead of the compound of Preparation Example A9 to prepare the compound 5- (biphenyl-4-yl) -9-bromo-7,7,13,13-tetramethyl-7,13-dihydro- indeno [1,2-b] acridine.

준비예 A1의 합성과정에서 bromobenzene 대신 1-bromonaphthalene, 3-bromobiphenyl, 2-bromophenanthrene, 2-bromo-9,9-dimethyl-9H-fluorene, 3-(4-bromophenyl)pyridine 등을 이용하여 R1, R4가 서로 다른 준비예를 합성할 수 있다. 단, 상기에 나열한 치환기는 본 발명을 예시하는 것일 뿐 본 발명의 준비예가 상기 준비예(Ar)에 의해 한정되는 것은 아니다.
Preparation Example A1 In the synthesis process A1, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 were removed by using bromobenzene instead of bromobenzene, 3-bromobiphenyl, 2-bromophenanthrene, 2-bromo-9,9- R 4 may be prepared in different preparations. However, the substituents listed above are only illustrative of the present invention, and the preparation examples of the present invention are not limited by the preparation examples (Ar).

2. 화합물의 제조 2. Preparation of compounds

2.1. 화합물 1의 제조2.1. Preparation of Compound (1)

Figure pat00057

Figure pat00057

합성예 1-1) 화합물 1-1의 제조Synthesis Example 1-1) Preparation of Compound 1-1

준비예 A1 화합물(2-bromo-9,9-dimethyl-10-phenyl-9,10-dihydroacridine) 10.0g (27.6mmol) 을 테트라히드로퓨란 200 mL에 녹이고, -78℃에서 n-BuLi(1.6 M in n-Hexane) 28.8 mL(24.0mmol)를 천천히 적가해 주었다. 30 분 동안 교반시킨 후, N,N-디메틸 포름아미드 1.8 mL(1.2당량)를 넣어주었다. 온도를 천천히 올려 2 시간 동안 교반한 후, NH4Cl 수용액과 증류수를 가해 반응을 종료시키고, 유기층을 분리하여 감압 제거한 후, 메탄올:n-헥산(1:1)로 재결정하여 화합물 9,9-dimethyl-10-phenyl-9,10-dihydroacridine-2-carbaldehyde 6.48g (20.7 mmol) (수율 75%)을 얻었다. Preparation Example 10 To 10.0 g (27.6 mmol) of the compound (2-bromo-9,9-dimethyl-10-phenyl-9,10-dihydroacridine) dissolved in 200 mL of tetrahydrofuran was added n-BuLi in n-hexane) (28.8 mL, 24.0 mmol) was slowly added dropwise. After stirring for 30 minutes, 1.8 mL (1.2 eq.) Of N, N-dimethylformamide was added. The reaction was terminated by adding an aqueous solution of NH4Cl and distilled water, and the organic layer was separated and removed under reduced pressure. The residue was recrystallized from methanol: n-hexane (1: 1) 10-phenyl-9,10-dihydroacridine-2-carbaldehyde (yield: 75%).

상기에서 얻어진 화합물 9,9-dimethyl-10-phenyl-9,10-dihydroacridine-2-carbaldehyde 6.48g (20.7 mmol), NaBH4 0.9 g(1.5당량)을 테트라히드로퓨란 80 mL에 녹이고 0℃로 냉각, 메탄올 40 mL을 천천히 적가해 주었다. 30분간 교반한 다음 증류수를 넣어 반응을 종료하고 에틸아세테이트로 추출, 감압 건조하여 컬럼 크로마토그래피(디클로로메탄/헥산=1/1)으로 화합물 (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)methanol 3.24 g (10.36mmol)(수율 50%)을 얻었다.6.48 g (20.7 mmol) of the compound 9,9-dimethyl-10-phenyl-9,10-dihydroacridine-2-carbaldehyde obtained above and 0.9 g (1.5 eq.) Of NaBH4 were dissolved in 80 mL of tetrahydrofuran, Methanol (40 mL) was slowly added dropwise. After stirring for 30 minutes, distilled water was added to complete the reaction. The reaction mixture was extracted with ethyl acetate, dried under reduced pressure, and purified by column chromatography (dichloromethane / hexane = 1/1) to obtain 9,9- dihydroacridin-2-yl) methanol 3.24 g (10.36 mmol) (yield 50%).

상기에서 얻어진 화합물 (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl)methanol 3.24 g (10.36mmol)을 반응용기에 넣은 후 질소 기류 하에 트리에틸포스파이트 80 mL를 넣고 녹인다. 다른 반응용기에 트리에틸포스파이트 40 mL를 넣고서 뚜껑을 열고 요오드 3.6 g(1당량)를 조금씩 넣어주면서 0℃에서 30분동안 교반하였다. 그 후 150?까지 온도를 올린 후 4시간 동안 교반하였다. 반응이 종료되면 감압증류를 통해 트리에틸포스파이트를 제거한 후 증류수로 세척하고 에틸아세테이트로 추출, 감압 건조하여 컬럼 크로마토그래피(에틸아세테이트/헥산=1/1)으로 화합물 1-1을 3.82g (8.80mmol)(수율 85%) 얻었다.
3.24 g (10.36 mmol) of the compound (9,9-dimethyl-10-phenyl-9,10-dihydroacridin-2-yl) methanol obtained above was dissolved in 80 mL of triethylphosphite under a nitrogen stream . Another reaction vessel was charged with 40 mL of triethylphosphite, the lid was opened, and 3.6 g (1 equivalent) of iodine was slowly added thereto, followed by stirring at 0 ° C for 30 minutes. Thereafter, the temperature was raised to 150 ° C, followed by stirring for 4 hours. After completion of the reaction, triethyl phosphite was removed by distillation under reduced pressure, and the residue was washed with distilled water, extracted with ethyl acetate, dried under reduced pressure, and purified by column chromatography (ethyl acetate / hexane = 1/1) mmol) (yield: 85%).

합성예 1-2) 화합물 1-2의 제조Synthesis Example 1-2) Preparation of Compound 1-2

Diphenylamine 5.0g (20.35mmol)을 N,N-디메틸포름아미드 100 mL에 녹인다음 0℃로 냉각, 다른 용기에 N,N-디메틸포름아미드 16 mL(203.8 mmol)을 넣고 0℃로 냉각한 다음 POCl3를 천천히 첨가해주었다. 이를 30분 동안 교반한 다음 트리페닐아민이 녹아있는 용기에 0℃에서 천천히 적가해 주었다. 이를 45℃에서 18시간 동안 더 교반한 다음 포화된 수산화나트륨 수용액을 천천히 부어주고 여기에 과량의 물을 넣고 저어주었다. 이때 고체가 생기는데 이를 여과한 후 물과 메탄올로 세척하여 화합물 1-2을 4.7 g (17.5mmol)(수율 86%) 얻었다.
Diphenylamine (5.0 g, 20.35 mmol) was dissolved in 100 mL of N, N-dimethylformamide and cooled to 0 ° C. To the other container was added 16 mL (203.8 mmol) of N, N-dimethylformamide, cooled to 0 ° C., Was slowly added. This was stirred for 30 minutes and then slowly added dropwise to the vessel containing triphenylamine at 0 ° C. It was further stirred at 45 < 0 > C for 18 hours, then saturated aqueous sodium hydroxide solution was poured slowly, and an excess amount of water was added thereto and stirred. At this time, a solid was formed, which was filtered and washed with water and methanol to obtain 4.7 g (17.5 mmol) of the compound 1-2 (yield: 86%).

합성예 1-3) 화합물 1의 제조Synthesis Example 1-3) Preparation of Compound 1

상기에서 얻어진 화합물 1-1를 3.82g (8.80mmol), 화합물 1-2를 2.46g (8.80mmol) 반응용기에 넣은 후, 감압 건조하였다. 질소 분위기를 만든 후 테트라히드로퓨란 200 mL를 넣고 녹인 다음 0℃로 냉각, 다른 용기에 칼륨터트부톡사이드(t-BuOK) 1,46 g (1.5당량)를 테트라히드로퓨란 10 mL에 녹여 이를 천천히 적가해 주었다. 0℃에서 2시간 동안 교반한 다음 증류수 150 mL를 넣고 교반하였다. 이때 고체가 생성되는데 이를 감압여과하여 고체를 얻었다. 메탄올, 에틸아세테이트로 세척하고 재결정하여 화합물 1을 2.52g(5.28mmol)(수율 60%) 얻었다.3.82 g (8.80 mmol) of the compound 1-1 thus obtained and 2.46 g (8.80 mmol) of the compound 1-2 were placed in a reaction vessel, followed by drying under reduced pressure. After adding 200 mL of tetrahydrofuran, the solution was cooled to 0 ° C. To another container, 1.46 g (1.5 equivalent) of potassium tert-butoxide (t-BuOK) was dissolved in 10 mL of tetrahydrofuran, I did it. After stirring at 0 ° C for 2 hours, 150 mL of distilled water was added and stirred. At this time, a solid was formed, which was filtered under reduced pressure to obtain a solid. Washed with methanol and ethyl acetate, and recrystallized to obtain 2.52 g (5.28 mmol) of Compound 1 (yield: 60%).

Elemental Analysis: C, 87.83; H, 6.32; N, 5.85 HRMS [M]+: 477Elemental Analysis: C, 87.83; H, 6.32; N, 5.85 HRMS [M] < + & gt ; : 477

1H NMR(CDCl3, 400 MHz) : δ 1.67(s, 6H), 6.10(d, 1H), 6.29(m, 4H), 6.50-6.63(m, 4H), 6.73-6.91(m, 6H), 7.02-7.05(m, 2H), 7.20(t, 6H), 7.47(d, 1H)
(M, 4H), 6.73-6.91 (m, 6H), 7.02 (d, IH) 2H), 7.20 (t, 6H), 7.47 (d, IH)

2.2. 화합물 2의 제조 2.2. Preparation of Compound 2

Figure pat00058

Figure pat00058

합성예 2-1) 화합물 2-1의 제조Synthesis Example 2-1) Preparation of Compound 2-1

합성예 1-1에서 준비예 A1 화합물을 사용하는 대신 준비예 A2 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 1-1 was synthesized in the same manner except that the compound of Preparation Example A2 was used instead of the preparation Example A1.

합성예 2-2) 화합물 2-2의 제조Synthesis Example 2-2) Preparation of Compound 2-2

합성예 1-2에서 Diphenylamine 대신 N-phenylnaphthalen-2-amine을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-2, except that N-phenylnaphthalen-2-amine was used instead of diphenylamine.

합성예 2-3) 화합물 2의 제조Synthesis Example 2-3) Preparation of Compound 2

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 2-1, 2-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 2-1 and 2-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 89.40; H, 6.25; N, 4.34 HRMS [M]+: 643
Elemental Analysis: C, 89.40; H, 6.25; N, 4.34 HRMS [M] < + & gt ; : 643

2.3. 화합물 3의 제조2.3. Preparation of Compound 3

Figure pat00059

Figure pat00059

합성예 3-1) 화합물 3-1의 제조Synthesis Example 3-1) Preparation of Compound 3-1

합성예 2-1과 동일한 방법으로 합성하였다.
Was synthesized in the same manner as Synthesis Example 2-1.

합성예 3-2) 화합물 3-2의 제조Synthesis Example 3-2) Preparation of Compound 3-2

준비예 A1 화합물(2-bromo-9,9-dimethyl-10-phenyl-9,10-dihydroacridine) 10.0g (27.6mmol) 을 테트라히드로퓨란 200 mL에 녹이고, -78℃에서 n-BuLi(1.6 M in n-Hexane) 28.8 mL(24.0mmol)를 천천히 적가해 주었다. 30 분 동안 교반시킨 후, N,N-디메틸 포름아미드 1.8 mL(1.2당량)를 넣어주었다. 온도를 천천히 올려 2 시간 동안 교반한 후, NH4Cl 수용액과 증류수를 가해 반응을 종료시키고, 유기층을 분리하여 감압 제거한 후, 메탄올:n-헥산(1:1)로 재결정하여 화합물 9,9-dimethyl-10-phenyl-9,10-dihydroacridine-2-carbaldehyde를 6.48g (20.7 mmol) (수율 75%)을 얻었다.
Preparation Example 10 To 10.0 g (27.6 mmol) of the compound (2-bromo-9,9-dimethyl-10-phenyl-9,10-dihydroacridine) dissolved in 200 mL of tetrahydrofuran was added n-BuLi in n-hexane) (28.8 mL, 24.0 mmol) was slowly added dropwise. After stirring for 30 minutes, 1.8 mL (1.2 eq.) Of N, N-dimethylformamide was added. The reaction was terminated by adding an aqueous solution of NH4Cl and distilled water, and the organic layer was separated and removed under reduced pressure. The residue was recrystallized from methanol: n-hexane (1: 1) 10-phenyl-9,10-dihydroacridine-2-carbaldehyde (yield: 75%).

합성예 3-3) 화합물3의 제조Synthesis Example 3-3) Preparation of Compound 3

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 3-1, 3-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3 except that the above-obtained Compounds 3-1 and 3-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 89.54; H, 6.52; N, 3.94 HRMS [M]+: 709
Elemental Analysis: C, 89.54; H, 6.52; N, 3.94 HRMS [M] < + & gt ; : 709

2.4. 화합물 4의 제조2.4. Preparation of compound 4

Figure pat00060

Figure pat00060

합성예 4-1) 화합물 4-1의 제조Synthesis Example 4-1) Preparation of Compound 4-1

합성예 1-1에서 준비예 A1 화합물 대신 준비예 A4 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example 1-1 was prepared in the same manner as Preparation Example A1, except that the compound of Preparation Example A4 was used instead of Preparation Example A1.

합성예 4-2) 화합물 4-2의 제조Synthesis Example 4-2) Preparation of Compound 4-2

합성예 1-2와 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-2.

합성예 4-3) 화합물 4의 제조Synthesis Example 4-3) Preparation of Compound 4

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 4-1, 4-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3 except that the above-obtained Compounds 4-1 and 4-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 88.60; H, 6.10; N, 5.30 HRMS [M]+: 527
Elemental Analysis: C, 88.60; H, 6.10; N, 5.30 HRMS [M] < + >: 527

2.5. 화합물 5의 제조2.5. Preparation of Compound 5

Figure pat00061

Figure pat00061

합성예 5-1) 화합물 5-1의 제조Synthesis Example 5-1) Preparation of Compound 5-1

합성예 1-1에서 준비예 A1 화합물 대신 준비예 A7 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 1-1 was prepared in the same manner except that the compound of Preparation Example A7 was used instead of the preparation example A1.

합성예 5-2) 화합물 5-2의 제조Synthesis Example 5-2) Preparation of Compound 5-2

합성예 2-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 2-2.

합성예 5-3) 화합물 5의 제조Synthesis Example 5-3) Preparation of Compound 5

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 5-1, 5-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the above-obtained Compounds 5-1 and 5-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 89.10; H, 6.90; N, 4.00 HRMS [M]+: 699
Elemental Analysis: C, 89.10; H, 6.90; N, 4.00 HRMS [M] < + & gt ; : 699

2.6. 화합물 6의 제조2.6. Preparation of Compound 6

Figure pat00062

Figure pat00062

합성예 6-1) 화합물 6-1의 제조Synthesis Example 6-1) Preparation of Compound 6-1

합성예 1-1에서 준비예 A1 화합물 대신 준비예 A8 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example 1-1 was prepared in the same manner as Preparation Example A-1 except that the compound of Preparation Example A8 was used instead of Preparation Example A1.

합성예 6-2) 화합물 6-2의 제조Synthesis Example 6-2) Preparation of Compound 6-2

합성예 1-2와 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-2.

합성예 6-3) 화합물 6의 제조Synthesis Example 6-3) Preparation of Compound 6

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 6-1, 6-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the compounds 6-1 and 6-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 88.77; H, 6.18; N, 5.05 HRMS [M]+: 553
Elemental Analysis: C, 88.77; H, 6. 18; N, 5.05. HRMS [M] < + & gt ; : 553

2. 7 화합물 7의 제조2. 7 Preparation of Compound 7

Figure pat00063

Figure pat00063

합성예 7-1) 화합물 7-1의 제조Synthesis Example 7-1) Preparation of Compound 7-1

합성예 1-1과 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-1.

합성예 7-2) 화합물 7-2의 제조Synthesis Example 7-2) Preparation of Compound 7-2

합성예 1-1와 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-1.

합성예 7-3) 화합물 7의 제조Synthesis Example 7-3) Preparation of Compound 7

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 7-1, 7-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the compounds 7-1 and 7-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 88.85; H, 6.44; N, 4.71 HRMS [M]+: 593
Elemental Analysis: C, 88.85; H, 6.44; N, 4.71 HRMS [M] < + & gt ; : 593

2. 8. 화합물 8의 제조2. 8. Preparation of compound 8

Figure pat00064

Figure pat00064

합성예 8-1) 화합물8-1의 제조Synthesis Example 8-1) Preparation of Compound 8-1

합성예 1-1과 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-1.

합성예 8-2) 화합물 8-2의 제조Synthesis Example 8-2) Preparation of Compound 8-2

합성예 3-2에서 준비예 A1 화합물 대신 준비예 A4 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example 3-2-2 Preparation Example A1 Instead of Compound A1 The title compound was synthesized in the same way except that Compound A4 was used.

합성예 8-3) 화합물 8의 제조Synthesis Example 8-3) Preparation of Compound 8

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 8-1, 8-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the compounds 8-1 and 8-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 89.40; H, 6.25; N, 4.34 HRMS [M]+: 643
Elemental Analysis: C, 89.40; H, 6.25; N, 4.34 HRMS [M] < + & gt ; : 643

2. 9. 화합물 9의 제조2. Preparation of 9

Figure pat00065

Figure pat00065

합성예 9-1) 화합물 9-1의 제조Synthesis Example 9-1) Preparation of Compound 9-1

합성예 5-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 5-1.

합성예 9-2) 화합물 9-2의 제조Synthesis Example 9-2) Preparation of Compound 9-2

합성예 3-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 3-2.

합성예 9-3) 화합물 9의 제조Synthesis Example 9-3) Preparation of Compound 9

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 9-1, 9-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the above-obtained Compounds 9-1 and 9-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 89.25; H, 7.10; N, 3.65 HRMS [M]+: 765
Elemental Analysis: C, 89.25; H, 7.10; N, 3.65 HRMS [M] < + & gt ; : 765

2.10. 화합물 10의 제조2.10. Preparation of Compound 10

Figure pat00066

Figure pat00066

합성예 10-1) 화합물 10-1의 제조Synthesis Example 10-1) Preparation of Compound 10-1

합성예 2-1과 동일한 방법으로 합성하였다.
Was synthesized in the same manner as Synthesis Example 2-1.

합성예 10-2) 화합물 10-2의 제조Synthesis Example 10-2) Preparation of Compound 10-2

합성예 3-2에서 준비예 A1 화합물 대신 준비예 A5 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example in Synthesis Example 3-2 The procedure of Preparation Example A1 was repeated except that the compound A5 was used in place of the compound A1.

합성예 10-3) 화합물 10의 제조Synthesis Example 10-3) Preparation of Compound 10

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 10-1, 10-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the compounds 10-1 and 10-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.37; H, 6.43; N, 3.19 HRMS [M]+: 875
Elemental Analysis: C, 90.37; H, 6.43; N, 3.19 HRMS [M] < + & gt ; : 875

3. 3. 준비예Preparation Example B의 합성( Synthesis of B ArAr -A--A- BrBr 구조) rescue)

3.1. 3.1. 준비예Preparation Example B1의 합성 Synthesis of B1

Figure pat00067
Figure pat00067

Figure pat00068

Figure pat00068

250ml 둥근 플라스크에 9,9-dimethyl-10-phenyl-9,10-dihydroacridine 6g (16.5mmol)와 bis(pinacolato)diboron 5.1g (1.2당량), [1,1 bis(diphenylphosphino)ferrocene] dichloropalladium(?) 0.36g (3 mol %), potassium acetate 4.8g (3당량) 을 1,4-dioxane 90ml를 넣고 질소상태에서 over night 동안 환류 교반시켰다. H2O를 넣어 반응을 종료 시킨 후, methylene chloride 를 첨가하여 H2O층과 유기층을 분리 시켰다. 감압 승온하여 용매를 제거 한 후, 컬럼 크로마토그래피를 통하여 9,9-dimethyl-10-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9,10-dihydroacridine 5.4g (13.2mmol)(수율 80%)을 얻었다.To a 250 ml round-bottomed flask was added 6 g (16.5 mmol) of 9,9-dimethyl-10-phenyl-9,10-dihydroacridine, 5.1 g (1.2 equivalent) of bis (pinacolato) diboron, and 1,1 bis (diphenylphosphino) ferrocene dichloropalladium ) And potassium acetate (4.8 g, 3 equivalents) were added to 90 ml of 1,4-dioxane, and the mixture was stirred under reflux in an atmosphere of nitrogen over night. H 2 O was added to terminate the reaction. Then, methylene chloride was added to separate the H 2 O layer and the organic layer. After the solvent was removed under reduced pressure, the residue was purified by column chromatography to obtain 9,9-dimethyl-10-phenyl-2- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- (13.2 mmol) of 9,10-dihydroacridine (yield 80%).

상기에서 얻어진 9,9-dimethyl-10-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9,10-dihydroacridine 5.4g (13.2mmol), 1,4-dibromobenzene (1당량), tetrakis(triphenylphosphine)palladium(0) 2.1g (5 mol %), potassium carbonate 15g (3당량) 을 1,4-dioxane 61ml, H2O 18ml 와 함께 250ml 둥근 플라스크에 넣고 질소 상태하에서 3시간 동안 환류 교반시켰다. 반응 종료 후, 반응액을 컬럼 크로마토그래피를 통하여 준비예 B1 화합물 2-(4-bromophenyl)-9,9-dimethyl-10-phenyl-9,10-dihydroacridine 4.63g(10.56mmol) (수율 80%)을 얻을 수 있었다.
5.4 g (13.2 mmol) of 9,9-dimethyl-10-phenyl-2- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- , 2.1 g (5 mol%) of tetrakis (triphenylphosphine) palladium (0 mol) and 15 g (3 eq.) Of potassium carbonate were mixed with 61 ml of 1,4-dioxane and 18 ml of H2O in a 250 ml round- And the mixture was refluxed under nitrogen for 3 hours. After completion of the reaction, the reaction solution was subjected to column chromatography to obtain 4.63 g (10.56 mmol) (yield 80%) of 2- (4-bromophenyl) -9,9-dimethyl-10-phenyl-9,10- .

3.2. 3.2. 준비예Preparation Example B2의 합성 Synthesis of B2

Figure pat00069
Figure pat00069

Figure pat00070

Figure pat00070

준비예 B1의 합성과정에서 1,4-dibromobenzene 대신 2,6-dibromonaphthalene 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example B1 Synthesis was carried out in the same manner except that 2,6-dibromonaphthalene was used instead of 1,4-dibromobenzene in the synthesis process.

3.3. 3.3. 준비예Preparation Example B3의 합성 Synthesis of B3

Figure pat00071
Figure pat00071

Figure pat00072

Figure pat00072

준비예 B1의 합성과정에서 1,4-dibromobenzene 대신 4,4'-dibromobiphenyl 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example B1 Synthesis was carried out in the same manner except that 4,4'-dibromobiphenyl was used instead of 1,4-dibromobenzene in the synthesis process.

3.4. 3.4. 준비예Preparation Example B4의 합성 Synthesis of B4

Figure pat00073
Figure pat00073

Figure pat00074

Figure pat00074

준비예 B1의 합성과정에서 9,9-dimethyl-10-phenyl-9,10-dihydroacridine 대신 2-bromo-9,9-dimethyl-10-(naphthalen-2-yl)-9,10-dihydroacridine을 사용하고, 1,4-dibromobenzene 대신 2,7-dibromo-9,9-dimethyl-9H-fluorene을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example B1 Using 2-bromo-9,9-dimethyl-10- (naphthalen-2-yl) -9,10-dihydroacridine instead of 9,9-dimethyl-10-phenyl-9,10-dihydroacridine , And 2,7-dibromo-9,9-dimethyl-9H-fluorene was used instead of 1,4-dibromobenzene.

3.5. 3.5. 준비예Preparation Example B5의 합성 Synthesis of B5

Figure pat00075
Figure pat00075

Figure pat00076

Figure pat00076

준비예 B1의 합성과정에서 9,9-dimethyl-10-phenyl-9,10-dihydroacridine 대신 10-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno[1,2-b]acridine을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example B1 was repeated except that 9-dimethyl-10-phenyl-9,10-dihydroacridine was used instead of 10-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro- [L, 2-b] acridine. ≪ / RTI >

3.6. 3.6. 준비예Preparation Example B6의 합성 Synthesis of B6

Figure pat00077
Figure pat00077

Figure pat00078

Figure pat00078

준비예 B1의 합성과정에서 9,9-dimethyl-10-phenyl-9,10-dihydroacridine 대신 10-bromo-7,7,13,13-tetramethyl-5-(naphthalen-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine을 사용하고, 1,4-dibromobenzene 대신 2,7-dibromo-9,9-dimethyl-9H-fluorene을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
10-bromo-7,7,13,13-tetramethyl-5- (naphthalen-2-yl) -7,13-dihydroacridine was used in place of 9,9-dimethyl- -dihydro-5H-indeno [1,2-b] acridine and 2,7-dibromo-9,9-dimethyl-9H-fluorene instead of 1,4-dibromobenzene.

3.7. 3.7. 준비예Preparation Example B7의 합성 Synthesis of B7

Figure pat00079
Figure pat00079

Figure pat00080

Figure pat00080

준비예 B1의 합성과정에서 9,9-dimethyl-10-phenyl-9,10-dihydroacridine 대신 10-bromo-5-(4-tert-butylphenyl)-7,7,13,13-tetramethyl-7,13-dihydro-5H-indeno[1,2-b]acridine을 사용하고, 1,4-dibromobenzene 대신 2,6-dibromonaphthalene을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
In the synthesis of Preparation B1, 10-bromo-5- (4-tert-butylphenyl) -7,7,13,13-tetramethyl-7,13 -dihydro-5H-indeno [1,2-b] acridine and using 2,6-dibromonaphthalene instead of 1,4-dibromobenzene.

4. 화합물의 제조4. Preparation of compounds

4.1. 화합물 11의 제조4.1. Preparation of Compound 11

Figure pat00081

Figure pat00081

합성예 11-1) 화합물 11-1의 제조Synthesis Example 11-1) Preparation of Compound 11-1

합성예 1-1에서 준비예 A1 화합물 대신 준비예 B1 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example 1-1 was prepared in the same manner as Preparation Example A1, except that Preparation Example B1 was used instead of Preparation Example A1.

합성예 11-2) 화합물 11-2의 제조Synthesis Example 11-2) Preparation of Compound 11-2

질소 분위기 하에서 1,4-dibromobenzene (5.13 g, 22.0 mmol) 및 diphenylamine (3.8 g, 22.6 mmol)을 톨루엔 70 mL에 녹인 후 트리스 벤질리딘 아세톤 다이 팔라듐 (0.4 g, 0.5 mmol)을 질소 하에서 넣었다. 그리고 P(t-Bu)3 (0.2 g, 0.9 mmol)을 반응 혼합물에 넣고, NaOBut(2.6 g, 27.1 mmol)을 투입하여, 반응 용액을 24시간 동안 환류 교반하였다. 반응이 종결된 후 얇은 실리카겔 패드에 고온 여과 하여 팔라듐을 제거하고, 헥산 대 디클로로메탄 7 대 3의 비율로 실리카겔 컬럼을 통과시켰다. 용매를 제거한 후 진공 건조하여 4-bromo-N,N-diphenylaniline (4.5 g, 19.3 mmol) (수율 88 %) 를 얻었다.1,4-dibromobenzene (5.13 g, 22.0 mmol) and diphenylamine (3.8 g, 22.6 mmol) were dissolved in 70 mL of toluene under a nitrogen atmosphere and then trisubenzylidine acetone dipalladium (0.4 g, 0.5 mmol) was added under nitrogen. Then, P (t-Bu) 3 (0.2 g, 0.9 mmol) was added to the reaction mixture, and NaOBut (2.6 g, 27.1 mmol) was added thereto and the reaction solution was refluxed for 24 hours. After the reaction was completed, the palladium was removed by hot filtration through a thin pad of silica gel and passed through a silica gel column at a ratio of hexane to dichloromethane 7: 3. The solvent was removed and vacuum drying was conducted to obtain 4-bromo-N, N-diphenylaniline (4.5 g, 19.3 mmol) (yield: 88%).

합성예 3-2에서 준비예 A1 화합물 대신 상기에서 얻어진 화합물 4-bromo-N,N-diphenylaniline을 이용하여 동일한 방법으로 4-(diphenylamino)benzaldehyde를 얻었다.
Preparative Example 3-2-2 4- (diphenylamino) benzaldehyde was obtained in the same manner as the compound 4-bromo-N, N-diphenylaniline obtained above instead of the compound A1.

합성예 11-3) 화합물 11의 제조Synthesis Example 11-3) Preparation of Compound 11

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 11-1, 11-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 11-1 and 11-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 89.49; H, 6.07; N, 4.44 HRMS [M]+: 629
Elemental Analysis: C, 89.49; H, 6.07; N, 4.44 HRMS [M] < + & gt ; : 629

4.2. 화합물 12의 제조4.2. Preparation of Compound 12

Figure pat00082

Figure pat00082

합성예 12-1) 화합물 12-1의 제조Synthesis Example 12-1) Preparation of Compound 12-1

합성예 1-1과 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-1.

합성예 12-2) 화합물 12-2의 제조Synthesis Example 12-2) Preparation of Compound 12-2

합성예 11-2에서 1,4-dibromobenzene 대신 2,7-dibromo-9,9-dimethyl-9H-fluorene을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 11-2 was synthesized in the same manner except that 2,7-dibromo-9,9-dimethyl-9H-fluorene was used instead of 1,4-dibromobenzene.

합성예 12-3) 화합물 12의 제조Synthesis Example 12-3) Preparation of Compound 12

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 12-1, 12-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 12-1 and 12-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 89.51; H, 6.31; N, 4.18 HRMS [M]+: 669
Elemental Analysis: C, 89.51; H, 6.31; N, 4.18 HRMS [M] < + & gt ; : 669

4. 3. 화합물 13의 제조4. Preparation of Compound 13

Figure pat00083

Figure pat00083

합성예 13-1) 화합물 13-1의 제조Synthesis Example 13-1) Preparation of Compound 13-1

합성예 4-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 4-1.

합성예 13-2) 화합물 13-2의 제조Synthesis Example 13-2) Preparation of Compound 13-2

합성예 12-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 12-2.

합성예 13-3) 화합물 13의 제조Synthesis Example 13-3) Preparation of Compound 13

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 13-1, 13-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 13-1 and 13-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 89.96; H, 6.15; N, 3.89 HRMS [M]+: 719
Elemental Analysis: C, 89.96; H, 6. 15; N, 3.89 HRMS [M] < + & gt ; : 719

4.4. 화합물 14의 제조4.4. Preparation of Compound 14

Figure pat00084

Figure pat00084

합성예 14-1) 화합물 14-1의 제조Synthesis Example 14-1) Preparation of Compound 14-1

합성예 1-1에서 준비예 A1 화합물 대신 2-bromo-10-(4-tert-butylphenyl)-9,9-dimethyl-9,10-dihydroacridine을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 1-1 was synthesized in the same manner except that 2-bromo-10- (4-tert-butylphenyl) -9,9-dimethyl-9,10-dihydroacridine was used instead of Preparation A1 compound.

합성예 14-2) 화합물 14-2의 제조Synthesis Example 14-2) Preparation of Compound 14-2

합성예 12-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 12-2.

합성예 14-3) 화합물 14의 제조Synthesis Example 14-3) Preparation of Compound 14

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 14-1, 14-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3 except that the above-obtained Compounds 14-1 and 14-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 89.21; H, 6.93; N, 3.85 HRMS [M]+: 725
Elemental Analysis: C, 89.21; H, 6.93; N, 3.85 HRMS [M] < + & gt ; : 725

4.5. 화합물 15의 제조4.5. Preparation of compound 15

Figure pat00085

Figure pat00085

합성예 15-1) 화합물 15-1의 제조Synthesis Example 15-1) Preparation of Compound 15-1

합성예 2-1과 동일한 방법으로 합성하였다.
Was synthesized in the same manner as Synthesis Example 2-1.

합성예 15-2) 화합물 15-2의 제조Synthesis Example 15-2) Preparation of Compound 15-2

합성예 12-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 12-2.

합성예 15-3) 화합물 15의 제조Synthesis Example 15-3) Preparation of Compound 15

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 15-1, 15-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 15-1 and 15-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.04; H, 6.40; N, 3.56 HRMS [M]+: 785
Elemental Analysis: C, 90.04; H, 6.40; N, 3.56 HRMS [M] < + & gt ; : 785

4.6. 화합물 16의 제조4.6. Preparation of Compound 16

Figure pat00086

Figure pat00086

합성예 16-1) 화합물 16-1의 제조Synthesis Example 16-1) Preparation of Compound 16-1

합성예 5-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 5-1.

합성예 16-2) 화합물 16-2의 제조Synthesis Example 16-2) Preparation of Compound 16-2

합성예 11-2에서 1,4-dibromobenzene 대신 4,4'-dibromobiphenyl을 이용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 11-2 was synthesized in the same manner except that 4,4'-dibromobiphenyl was used instead of 1,4-dibromobenzene.

합성예 16-3) 화합물 16의 제조Synthesis Example 16-3) Preparation of Compound 16

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 16-1, 16-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3 except that the above-obtained Compounds 16-1 and 16-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 89.73; H, 6.78; N, 3.49 HRMS [M]+: 801
Elemental Analysis: C, 89.73; H, 6. 78; N, 3.49 HRMS [M] < + & gt ; : 801

4.7. 화합물 17의 제조4.7. Preparation of Compound 17

Figure pat00087

Figure pat00087

합성예 17-1) 화합물 17-1의 제조Synthesis Example 17-1) Preparation of Compound 17-1

합성예 11-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as Synthesis Example 11-1.

합성예 17-2) 화합물 17-2의 제조Synthesis Example 17-2) Preparation of Compound 17-2

합성예 1-2와 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-2.

합성예 17-3) 화합물 17의 제조Synthesis Example 17-3) Preparation of Compound 17

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 17-1, 17-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 17-1 and 17-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 88.77; H, 6.18; N, 5.05 HRMS [M]+: 553
Elemental Analysis: C, 88.77; H, 6. 18; N, 5.05. HRMS [M] < + & gt ; : 553

4.8. 화합물 18의 제조4.8. Preparation of Compound 18

Figure pat00088

Figure pat00088

합성예 18-1) 화합물 18-1의 제조Synthesis Example 18-1) Preparation of Compound 18-1

합성예 1-1에서 준비예 A1 화합물 대신 준비예 B4 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example 1-1 was prepared in the same manner as Preparation Example B-1 except that the compound of Preparation Example B4 was used instead of Preparation Example A1.

합성예 18-2) 화합물 18-2의 제조Synthesis Example 18-2) Preparation of Compound 18-2

합성예 2-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 2-2.

합성예 18-3) 화합물 18의 제조Synthesis Example 18-3) Preparation of Compound 18

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 18-1, 18-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 18-1 and 18-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 89.96; H, 6.15; N, 3.89 HRMS [M]+: 719
Elemental Analysis: C, 89.96; H, 6. 15; N, 3.89 HRMS [M] < + & gt ; : 719

4.9. 화합물 19의 제조4.9. Preparation of Compound 19

Figure pat00089

Figure pat00089

합성예 19-1) 화합물 19-1의 제조Synthesis Example 19-1) Preparation of Compound 19-1

합성예 1-1에서 준비예 A1 화합물 대신 준비예 B5 화합물을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 1-1 was prepared in the same manner except that Preparation Example B5 was used instead of Preparation Example A1.

합성예 19-2) 화합물 19-2의 제조Synthesis Example 19-2) Preparation of Compound 19-2

합성예 2-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 2-2.

합성예 19-3) 화합물 19의 제조Synthesis Example 19-3) Preparation of Compound 19

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 19-1, 19-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the above-obtained Compounds 19-1 and 19-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 89.96; H, 6.15; N, 3.89 HRMS [M]+: 719
Elemental Analysis: C, 89.96; H, 6. 15; N, 3.89 HRMS [M] < + & gt ; : 719

4.10. 화합물 20의 제조4.10. Preparation of Compound 20

Figure pat00090

Figure pat00090

합성예 20-1) 화합물 20-1의 제조Synthesis Example 20-1) Preparation of Compound 20-1

합성예 19-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 19-1.

합성예 20-2) 화합물 20-2의 제조Synthesis Example 20-2) Preparation of Compound 20-2

합성예 3-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 3-2.

합성예 20-3) 화합물 20의 제조Synthesis Example 20-3) Preparation of Compound 20

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 20-1, 20-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 20-1 and 20-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.04; H, 6.40; N, 3.56 HRMS [M]+: 785
Elemental Analysis: C, 90.04; H, 6.40; N, 3.56 HRMS [M] < + & gt ; : 785

4.11. 화합물 21의 제조4.11. Preparation of Compound 21

Figure pat00091

Figure pat00091

합성예 21-1) 화합물 21-1의 제조Synthesis Example 21-1) Preparation of Compound 21-1

합성예 19-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 19-1.

합성예 21-2) 화합물 21-2의 제조Synthesis Example 21-2) Preparation of Compound 21-2

합성예 8-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 8-2.

합성예 21-3) 화합물 21의 제조Synthesis Example 21-3) Preparation of Compound 21

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 21-1, 21-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 21-1 and 21-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.39; H, 6.26; N, 3.35 HRMS [M]+: 835
Elemental Analysis: C, 90.39; H, 6.26; N, 3.35 HRMS [M] < + & gt ; : 835

4.12. 화합물 22의 제조4.12. Preparation of Compound 22

Figure pat00092

Figure pat00092

합성예 22-1) 화합물 22-1의 제조Synthesis Example 22-1) Preparation of Compound 22-1

합성예 18-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 18-1.

합성예 22-2) 화합물 22-2의 제조Synthesis Example 22-2) Preparation of Compound 22-2

합성예 8-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 8-2.

합성예 22-3) 화합물 22의 제조Synthesis Example 22-3) Preparation of Compound 22

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 22-1, 22-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the compounds 22-1 and 22-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.39; H, 6.26; N, 3.35 HRMS [M]+: 835
Elemental Analysis: C, 90.39; H, 6.26; N, 3.35 HRMS [M] < + & gt ; : 835

4. 13. 4. 13. 실시예Example 23의 제조 23 manufacture

Figure pat00093

Figure pat00093

합성예 23-1) 화합물 23-1의 제조Synthesis Example 23-1) Preparation of Compound 23-1

합성예 19-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 19-1.

합성예 23-2) 화합물 23-2의 제조Synthesis Example 23-2) Preparation of Compound 23-2

합성예 3-2에서 준비예 A1 화합물 대신 준비예 A7 화합물 9-bromo-5-(4-tert-butylphenyl)-7,7,13,13-tetramethyl-7,13-dihydro-5H-indeno[1,2-b]acridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example in Synthesis Example 3-2 Preparation Example A7 instead of Compound A1 A compound 9-bromo-5- (4-tert-butylphenyl) -7,7,13,13-tetramethyl-7,13-dihydro- , 2-b] acridine was used as the starting material.

합성예 23-3) 화합물 23의 제조Synthesis Example 23-3) Preparation of Compound 23

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 23-1, 23-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 23-1 and 23-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.15; H, 6.93; N, 2.92 HRMS [M]+: 957
Elemental Analysis: C, 90.15; H, 6.93; N, 2.92 HRMS [M] < + & gt ; : 957

4.14. 화합물 24의 제조4.14. Preparation of Compound 24

Figure pat00094

Figure pat00094

합성예 24-1) 화합물 24-1의 제조Synthesis Example 24-1) Preparation of Compound 24-1

합성예 11-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as Synthesis Example 11-1.

합성예 24-2) 화합물 24-2의 제조Synthesis Example 24-2) Preparation of Compound 24-2

합성예 12-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 12-2.

합성예 24-3) 화합물 24의 제조Synthesis Example 24-3) Preparation of Compound 24

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 24-1, 24-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 24-1 and 24-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.04; H, 6.21; N, 3.75 HRMS [M]+: 745
Elemental Analysis: C, 90.04; H, 6.21; N, 3.75 HRMS [M] < + & gt ; : 745

4.15. 화합물 25의 제조4.15. Preparation of Compound 25

Figure pat00095

Figure pat00095

합성예 25-1) 화합물 25-1의 제조Synthesis Example 25-1) Preparation of Compound 25-1

합성예 19-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 19-1.

합성예 25-2) 화합물 25-2의 제조Synthesis Example 25-2) Preparation of Compound 25-2

합성예 12-2과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 12-2.

합성예 25-3) 화합물 25의 제조Synthesis Example 25-3) Preparation of Compound 25

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 25-1, 25-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the above-obtained Compounds 25-1 and 25-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 90.45; H, 6.31; N, 3.25 HRMS [M]+: 861
Elemental Analysis: C, 90.45; H, 6.31; N, 3.25 HRMS [M] < + & gt ; : 861

4.16. 화합물 26의 제조4.16. Preparation of Compound 26

Figure pat00096

Figure pat00096

합성예 26-1) 화합물 26-1의 제조Synthesis Example 26-1) Preparation of Compound 26-1

합성예 19-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 19-1.

합성예 26-2) 화합물 26-2의 제조Synthesis Example 26-2) Preparation of Compound 26-2

합성예 3-2에서 준비예 A1 화합물 대신 준비예 B2 화합물 9-bromo-5-(4-tert-butylphenyl)-7,7,13,13-tetramethyl-7,13-dihydro-5H-indeno[1,2-b]acridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example 3-2-2 Preparation B2 Compound 9-bromo-5- (4-tert-butylphenyl) -7,7,13,13-tetramethyl-7,13-dihydro-5H-indeno [1 , 2-b] acridine was used as the starting material.

합성예 26-3) 화합물 26의 제조Synthesis Example 26-3) Preparation of Compound 26

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 26-1, 26-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Synthesis was conducted in the same manner as in Synthesis Example 1-3, except that the compounds 26-1 and 26-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.75; H, 6.18; N, 3.07 HRMS [M]+: 911
Elemental Analysis: C, 90.75; H, 6. 18; N, 3.07 HRMS [M] < + & gt ; : 911

4.17. 4.17. 실시예Example 27의 제조 27 manufacture

Figure pat00097

Figure pat00097

합성예 27-1) 화합물 27-1의 제조Synthesis Example 27-1) Preparation of Compound 27-1

합성예 11-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as Synthesis Example 11-1.

합성예 27-2) 화합물 27-2의 제조Synthesis Example 27-2) Preparation of Compound 27-2

합성예 3-2에서 준비예 A1 화합물 대신 2-(7-bromo-9,9-dimethyl-9H-fluoren-2-yl)-9,9-dimethyl-10-phenyl-9,10-dihydroacridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example 3-2 In the same manner as in Preparation Example 3-2 except using 2- (7-bromo-9,9-dimethyl-9H-fluoren-2-yl) -9,9-dimethyl-10-phenyl-9,10-dihydroacridine Were synthesized in the same manner.

합성예 27-3) 화합물 27의 제조Synthesis Example 27-3) Preparation of Compound 27

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 27-1, 27-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 27-1 and 27-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.45; H, 6.31; N, 3.25 HRMS [M]+: 861
Elemental Analysis: C, 90.45; H, 6.31; N, 3.25 HRMS [M] < + & gt ; : 861

4.18. 화합물 28의 제조4.18. Preparation of Compound 28

Figure pat00098

Figure pat00098

합성예 28-1) 화합물 28-1의 제조Synthesis Example 28-1) Preparation of Compound 28-1

합성예 19-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 19-1.

합성예 28-2) 화합물 28-2의 제조Synthesis Example 28-2) Preparation of Compound 28-2

합성예 3-2에서 준비예 A1 화합물 대신 2-(7-bromo-9,9-dimethyl-9H-fluoren-2-yl)-10-(4-tert-butylphenyl)-9,9-dimethyl-9,10-dihydroacridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
9-dimethyl-9H-fluoren-2-yl) -10- (4-tert-butylphenyl) -9,9-dimethyl-9 , 10-dihydroacridine were used as the starting materials.

합성예 28-3) 화합물 28의 제조Synthesis Example 28-3) Preparation of Compound 28

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 28-1, 28-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the compounds 28-1 and 28-2 obtained above were used instead of the compounds 1-1 and 1-2.

Elemental Analysis: C, 90.73; H, 6.69; N, 2.58 HRMS [M]+: 1083
Elemental Analysis: C, 90.73; H, 6.69; N, 2.58 HRMS [M] < + & gt ; : 1083

4.19. 화합물 29의 제조4.19. Preparation of Compound 29

*

Figure pat00099

*
Figure pat00099

합성예 29-1) 화합물 29-1의 제조Synthesis Example 29-1) Preparation of Compound 29-1

9-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno[1,2-b]acridine 7.92g (16.5mmol)와 bis(pinacolato)diboron 5.1g (1.2당량), [1,1 bis(diphenylphosphino)ferrocene] dichloropalladium(Ⅱ) 0.36g (3 mol %), potassium acetate 4.8g (3당량) 을 1,4-dioxane 90ml를 250ml 둥근 플라스크에 넣고 질소상태에서 over night 동안 환류 교반 시켰다. H2O를 넣어 반응을 종료 시킨 후, methylene chloride 를 첨가하여 H2O층과 유기층을 분리 시켰다. 감압 승온하여 용매를 제거 한 후, 컬럼 크로마토그래피를 통하여 7,7,13,13-tetramethyl-5-phenyl-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine 6.58g (12.5mmol)(수율 76%)을 얻었다.
(16.5 mmol) of 9-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H- indeno [1,2- b] acridine and 5.1 g of bis (pinacolato) diboron 0.36 g (3 mol%) of [1,1 bis (diphenylphosphino) ferrocene] dichloropalladium (II) and 4.8 g (3 eq.) Of potassium acetate were placed in a 250 ml round- over-night. H 2 O was added to terminate the reaction. Then, methylene chloride was added to separate the H 2 O layer and the organic layer. After the solvent was removed under reduced pressure, the solvent was removed by column chromatography to obtain 7,7,13,13-tetramethyl-5-phenyl-9- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- -yl) -7,13-dihydro-5H-indeno [1,2-b] acridine (yield: 76%).

합성예 29-2) 화합물 29-2의 제조Synthesis Example 29-2) Preparation of Compound 29-2

질소 분위기 하에서 2,7-dibromo-9,9-dimethyl-9H-fluorene (7.74 g, 22.0mmol) 및 diphenylamine (3.8 g, 22.6mmol)을 톨루엔 70 mL에 녹인 후 트리스 벤질리딘 아세톤 다이 팔라듐 (0.4 g, 0.5 mmol)을 질소 하에서 넣었다. 그리고 P(t-Bu)3 (0.2 g, 0.9 mmol)을 반응 혼합물에 넣고, NaOBut(2.6 g, 27.1 mmol)을 투입하여, 반응 용액을 24시간 동안 환류 교반하였다. 반응이 종결된 후 얇은 실리카겔 패드에 고온 여과 하여 팔라듐을 제거하고, 헥산 대 디클로로메탄 7 대 3의 비율로 실리카겔 컬럼을 통과시켰다. 용매를 제거한 후 진공 건조하여 7-bromo-9,9-dimethyl-N,N-diphenyl-9H-fluoren-2-amine (8.05 g, 18.5mmol) (수율 84%) 를 얻었다.
2,7-dibromo-9,9-dimethyl-9H-fluorene (7.74 g, 22.0 mmol) and diphenylamine (3.8 g, 22.6 mmol) were dissolved in 70 mL of toluene under a nitrogen atmosphere and then 0.4 g of tribenzylideneacetone dipalladium , 0.5 mmol) were placed under nitrogen. Then, P (t-Bu) 3 (0.2 g, 0.9 mmol) was added to the reaction mixture, and NaOBut (2.6 g, 27.1 mmol) was added thereto and the reaction solution was refluxed for 24 hours. After the reaction was completed, the palladium was removed by hot filtration through a thin pad of silica gel and passed through a silica gel column at a ratio of hexane to dichloromethane 7: 3. The solvent was removed and vacuum drying was conducted to obtain 8.05 g (18.5 mmol) of 7-bromo-9,9-dimethyl-N, N-diphenyl-9H-fluoren-2-amine (yield: 84%).

합성예 29-3) 화합물 29의 제조Synthesis Example 29-3) Preparation of Compound 29

합성예 29-2 에서 합성된 화합물 7,7,13,13-tetramethyl-5-phenyl-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine 5.36g(12.5mmol)과 합성예 29-1에서 합성된 화합물 7,7,13,13-tetramethyl-5-phenyl-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine (1당량), tetrakis(triphenylphosphine)palladium (0) 2.0g (5 mol %), potassium carbonate 13g (3당량) 을 1,4-dioxane 61ml, H2O 18ml 와 함께 250ml 둥근 플라스크에 넣고 질소 상태하에서 3시간 동안 환류 교반 시켰다. 반응 종료 후, 반응액을 컬럼 크로마토그래피를 통하여 9,9-dimethyl-N,N-diphenyl-7-(7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno[1,2-b]acridin-9-yl)-9H-fluoren-2-amine 4.47g (5.9mmol) (수율 47%) 을 얻을 수 있었다.The compound 7,7,13,13-tetramethyl-5-phenyl-9- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- (12.5 mmol) of 13-dihydro-5H-indeno [1,2-b] acridine and the compound 7,7,13,13-tetramethyl-5-phenyl- 9- , 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -7,13-dihydro-5H-indeno [1,2- b] acridine (1 equiv), tetrakis (triphenylphosphine) palladium (5 mol%) and 13 g (3 equivalents) of potassium carbonate were placed in a 250 ml round-bottom flask together with 61 ml of 1,4-dioxane and 18 ml of H 2 O and refluxed under nitrogen for 3 hours. After completion of the reaction, the reaction mixture was subjected to column chromatography to obtain 9,9-dimethyl-N, N-diphenyl-7- (7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro- (4.7 g, 5.9 mmol) (47% yield) of [1,2-b] acridin-9-yl) -9H-fluoren-

Elemental Analysis: C, 89.96; H, 6.36; N, 3.68 HRMS [M]+: 759
Elemental Analysis: C, 89.96; H, 6. 36; N, 3.68 HRMS [M] < + & gt ; : 759

4.20. 화합물 30의 제조4.20. Preparation of Compound 30

Figure pat00100

Figure pat00100

합성예 30-1) 화합물 30-1의 제조Synthesis Example 30-1) Preparation of Compound 30-1

합성예 29-1에서 9-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno[1,2-b]acridine 대신 9-bromo-7,7,13,13-tetramethyl-5-(naphthalen-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno [1,2- b] acridine in Synthesis Example 29-1 instead of 9- Synthesis was carried out in the same way except that 13,13-tetramethyl-5- (naphthalen-2-yl) -7,13-dihydro-5H-indeno [1,2- b] acridine was used.

합성예 30-2) 화합물 30-2의 제조Synthesis Example 30-2) Preparation of Compound 30-2

7,7,13,13-tetramethyl-5-(naphthalen-2-yl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine 7.6g (13.2mmol), 2,7-dibromo-9,9-dimethyl-9H-fluorene (1당량), tetrakis(triphenylphosphine)palladium (0) 2.1g (5 mol %), potassium carbonate 15g (3당량) 을 1,4-dioxane 61ml, H2O 18ml 와 함께 250ml 둥근 플라스크에 넣고 질소 상태하에서 3시간 동안 환류 교반 시켰다. 반응 종료 후, 반응액을 컬럼 크로마토그래피를 통하여 9-(7-bromo-9,9-dimethyl-9H-fluoren-2-yl)-7,7,13,13-tetramethyl-5-(naphthalen-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine 6.99g(9.7mmol) (수율 73%) 을 얻을 수 있었다.
7,7,13,13-tetramethyl-5- (naphthalen-2-yl) -9- (4,4,5,5-tetramethyl- 1,3,2-dioxaborolan- (13.2 mmol), 2,7-dibromo-9,9-dimethyl-9H-fluorene (1 eq.), and tetrakis (triphenylphosphine) palladium (5 mol%) and 15 g (3 equivalents) of potassium carbonate were placed in a 250 ml round-bottomed flask together with 61 ml of 1,4-dioxane and 18 ml of H2O, and the mixture was refluxed under nitrogen for 3 hours. After completion of the reaction, the reaction mixture was subjected to column chromatography to obtain 9- (7-bromo-9,9-dimethyl-9H-fluoren-2-yl) -7,7,13,13-tetramethyl- 5- (naphthalen- -yl) -7,13-dihydro-5H-indeno [l, 2-b] acridine as a white solid (9.7 mmol, yield 73%).

합성예 30-3) 화합물 30의 제조Synthesis Example 30-3) Preparation of Compound 30

합성예 30-2 에서 합성된 화합물 9-(7-bromo-9,9-dimethyl-9H-fluoren-2-yl)-7,7,13,13-tetramethyl-5-(naphthalen-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine 6.99g(9.7mmol)과 합성예 30-1에서 합성된 화합물 7,7,13,13-tetramethyl-5-(naphthalen-2-yl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine (1당량), tetrakis(triphenylphosphine)palladium (0) 1.5g (5 mol %), potassium carbonate 10g (3당량) 을 1,4-dioxane 61ml, H2O 18ml 와 함께 250ml 둥근 플라스크에 넣고 질소 상태하에서 3시간 동안 환류 교반 시켰다. 반응 종료 후, 반응액을 컬럼 크로마토그래피를 통하여 9-(9,9-dimethyl-7-(11,11,13,13-tetramethyl-5-(naphthalen-2-yl)-11,13-dihydro-5H-indeno[2,1-b]acridin-9-yl)-9H-fluoren-2-yl)-7,7,13,13-tetramethyl-5-(naphthalen-2-yl)-7,13-dihydro-5H-indeno[1,2-b]acridine 7.75g (7.1mmol) (수율 68%) 을 얻을 수 있었다.Synthesis of Compound 9- (7-bromo-9,9-dimethyl-9H-fluoren-2-yl) -7,7,13,13-tetramethyl- 5- (naphthalen- (9.7 mmol) of the compound 7,7,13,13-tetramethyl-5- (naphthalen-2-yl) -7,13-dihydro-5H- -yl) -9- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -7,13-dihydro-5H- indeno [1,2- b] acridine 1.5 g (5 mol%) of tetrakis (triphenylphosphine) palladium (0) and 10 g (3 equivalents) of potassium carbonate were placed in a 250 ml round-bottomed flask with 61 ml of 1,4-dioxane and 18 ml of H 2 O, And the mixture was refluxed and stirred. After completion of the reaction, the reaction solution was subjected to column chromatography to obtain 9- (9,9-dimethyl-7- (11,11,13,13-tetramethyl-5- (naphthalen- 5H-indeno [2,1-b] acridin-9-yl) -9H-fluoren-2-yl) -7,7,13,13-tetramethyl- 5- (naphthalen- dihydro-5H-indeno [1,2-b] acridine (yield: 68%).

Elemental Analysis: C, 91.17; H, 6.27; N, 2.56 HRMS [M]+: 1091
Elemental Analysis: C, 91.17; H, 6. 27; N, 2.56 HRMS [M] < + & gt ; : 1091

4.21. 화합물 31의 제조4.21. Preparation of Compound 31

Figure pat00101

Figure pat00101

합성예 31-1) 화합물 31-1의 제조Synthesis Example 31-1) Preparation of Compound 31-1

준비예 B4의 합성과정에서 동일한 방법으로 합성하였다.
Preparation Example B4 was synthesized in the same manner as in the synthesis.

합성예 31-2) 화합물 31-2의 제조Synthesis Example 31-2) Preparation of Compound 31-2

합성예 29-1에서 9-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno[1,2-b]acridine 대신 2-bromo-9,9-dimethyl-10-phenyl-9,10-dihydroacridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Bromo-9,9-dihydro-5H-indeno [1,2-b] acridine instead of 9-bromo-7,7,13,13-tetramethyl- dimethyl-10-phenyl-9,10-dihydroacridine.

합성예 31-3) 화합물 31의 제조Synthesis Example 31-3) Preparation of Compound 31

합성예 30-3에서 합성예 30-2의 화합물 대신 합성예 31-1의 화합물 2-(7-bromo-9,9-dimethyl-9H-fluoren-2-yl)-9,9-dimethyl-10-(naphthalen-2-yl)-9,10-dihydroacridine, 합성예 30-1의 화합물 대신 합성예 31-2의 화합물 9,9-dimethyl-10-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9,10-dihydroacridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.9-dimethyl-9H-fluoren-2-yl) -9,9-dimethyl-10-quinolinone was obtained in the same manner as in Synthesis Example 30-3, - (naphthalen-2-yl) -9,10-dihydroacridine, the compound of Synthesis Example 31-2 was used instead of the compound of Synthesis Example 30-1, 9,9-dimethyl- -tetramethyl-1,3,2-dioxaborolan-2-yl) -9,10-dihydroacridine.

Elemental Analysis: C, 90.33; H, 6.21; N, 3.45 HRMS [M]+: 809
Elemental Analysis: C, 90.33; H, 6.21; N, 3.45 HRMS [M] < + & gt ; : 809

4.22. 화합물 32의 제조4.22. Preparation of Compound 32

Figure pat00102

Figure pat00102

합성예 32-1) 화합물 32-1의 제조Synthesis Example 32-1) Preparation of Compound 32-1

준비예 B1의 합성과정에서 1,4-dibromobenzene 대신 2,7-dibromo-9,9-dimethyl-9H-fluorene을 이용한 것을 제외하고 동일한 방법으로 합성하였다.
Preparation Example B1 Synthesis was carried out in the same manner except that 2,7-dibromo-9,9-dimethyl-9H-fluorene was used instead of 1,4-dibromobenzene in the synthesis process.

합성예 32-2) 화합물 32-2의 제조Synthesis Example 32-2) Preparation of Compound 32-2

합성예 29-1에서 9-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno[1,2-b]acridine 대신 준비예 B5의 화합물 9-(4-bromophenyl)-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno[1,2-b]acridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
The same procedures as described in Synthesis Example 29-1 were repeated except that 9-bromo-7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno [ 4-bromophenyl) -7,7,13,13-tetramethyl-5-phenyl-7,13-dihydro-5H-indeno [1,2-b] acridine.

합성예 32-3) 화합물 32의 제조Synthesis Example 32-3) Preparation of Compound 32

합성예 30-3에서 합성예 30-2의 화합물 대신 합성예 32-1의 화합물 2-(7-bromo-9,9-dimethyl-9H-fluoren-2-yl)-9,9-dimethyl-10-phenyl-9,10-dihydroacridine, 합성예 30-1의 화합물 대신 합성예 32-2의 화합물 7,7,13,13-tetramethyl-5-phenyl-9-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-7,13-dihydro-5H-indeno[1,2-b]acridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.9-dimethyl-9H-fluoren-2-yl) -9,9-dimethyl-10-quinolinecarboxylate instead of the compound of Synthesis Example 30-2 in Synthesis Example 30-3 phenyl-9,10-dihydroacridine was obtained in the same manner as in Synthesis Example 30-1 except that 7,7,13,13-tetramethyl-5-phenyl-9- (4- (4,4,5,5- 5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) -7,13-dihydro-5H-indeno [1,2- b] acridine.

Elemental Analysis: C, 90.72; H, 6.34; N, 2.94 HRMS [M]+: 951
Elemental Analysis: C, 90.72; H, 6.34; N, 2.94 HRMS [M] < + & gt ; : 951

4.23. 화합물 33의 제조4.23. Preparation of Compound 33

Figure pat00103

Figure pat00103

합성예 33-1) 화합물 33-1의 제조Synthesis Example 33-1) Production of Compound 33-1

합성예 32-2와 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 32-2.

합성예 33-2) 화합물 33의 제조Synthesis Example 33-2) Preparation of Compound 33

합성예 30-3에서 합성예 30-2의 화합물 대신 10-(4-bromophenyl)-12,12,13,13-tetramethyl-5-phenyl-12,13-dihydro-5H-indeno[2,1-a]acridine, 합성예 30-1의 화합물 대신 7,7,13,13-tetramethyl-5-phenyl-9-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-7,13-dihydro-5H-indeno[1,2-b]acridine 을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 30-3 was repeated except that 10- (4-bromophenyl) -12,12,13,13-tetramethyl-5-phenyl-12,13-dihydro-5H-indeno [ a] acridine, instead of the compound of Synthesis Example 30-1, 7,7,13,13-tetramethyl-5-phenyl- 9- (4- (4,4,5,5-tetramethyl- 1,3,2-dioxaborolan- 2-yl) phenyl) -7,13-dihydro-5H-indeno [1,2-b] acridine.

*Elemental Analysis: C, 90.72; H, 6.34; N, 2.94 HRMS [M]+: 951
* Elemental Analysis: C, 90.72; H, 6.34; N, 2.94 HRMS [M] < + & gt ; : 951

4.24. 화합물 34의 제조4.24. Preparation of Compound 34

Figure pat00104

Figure pat00104

합성예 34-1) 화합물 34-1의 제조Synthesis Example 34-1) Preparation of Compound 34-1

합성예 1-1과 동일한 방법으로 합성하였다.
Synthesis was carried out in the same manner as in Synthesis Example 1-1.

합성예 34-2) 화합물 34-2의 제조Synthesis Example 34-2) Preparation of Compound 34-2

합성예 11-2에서 1,4-dibromobenzene 대신 3,6-dibromo-9H-carbazole을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 11-2 was synthesized in the same manner except that 3,6-dibromo-9H-carbazole was used instead of 1,4-dibromobenzene.

합성예 34-3) 화합물 34의 제조Synthesis Example 34-3) Preparation of Compound 34

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 34-1, 34-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Except for using the compounds 34-1 and 34-2 obtained above in place of the compounds 1-1 and 1-2 in Synthesis Example 1-3.

Elemental Analysis: C, 87.82; H, 5.64; N, 6.54 HRMS [M]+: 641
Elemental Analysis: C, 87.82; H, 5.64; N, 6.54 HRMS [M] < + & gt ; : 641

4.25. 화합물 35의 제조4.25. Preparation of Compound 35

Figure pat00105

Figure pat00105

합성예 35-1) 화합물 35-1의 제조Synthesis Example 35-1) Production of Compound 35-1

합성예 5-1과 동일한 방법으로 합성하였다.
Synthesis was conducted in the same manner as in Synthesis Example 5-1.

합성예 35-2) 화합물 35-2의 제조Synthesis Example 35-2) Preparation of Compound 35-2

합성예 11-2에서 1,4-dibromobenzene 대신 5,5'-dibromo-2,2'-bipyridine을 사용한 것을 제외하고 동일한 방법으로 합성하였다.
Synthesis Example 11-2 was synthesized in the same manner except that 5,5'-dibromo-2,2'-bipyridine was used instead of 1,4-dibromobenzene.

합성예 35-3) 화합물 35의 제조Synthesis Example 35-3) Preparation of Compound 35

합성예 1-3에서 화합물 1-1, 1-2 대신 상기에서 얻어진 화합물 35-1, 35-2를 사용한 것을 제외하고 동일한 방법으로 합성하였다.Was synthesized in the same manner as in Synthesis Example 1-3, except that the above-obtained Compounds 35-1 and 35-2 were used instead of Compounds 1-1 and 1-2.

Elemental Analysis: C, 86.53; H, 6.51; N, 6.96 HRMS [M]+: 803
Elemental Analysis: C, 86.53; H, 6.51; N, 6.96 HRMS [M] < + & gt ; : 803

[실시예 1] 내지 [실시예 35]의 제조Preparation of [Examples 1] to [Example 35]

유기 EL 소자의 제조 및 평가 Preparation and evaluation of organic EL device

ITO(Indium tin oxide)가 1500 Å의 두께로 박막 코팅된 유리 기판을 증류수 초음파로 세척하였다. 증류수 세척이 끝나면 이소프로필 알코올, 아세톤, 메탄올 등의 용제로 초음파 세척을 하고 건조시킨 후 플라즈마 세정기로 이송시킨 다음 산소 플라즈마를 이용하여 상기 기판을 5분간 세정한 후 진공 증착기로 기판을 이송하였다. Glass substrate coated with ITO (Indium tin oxide) thin film with thickness of 1500 Å was cleaned with distilled water ultrasonic wave. After the distilled water was washed, the substrate was ultrasonically washed with a solvent such as isopropyl alcohol, acetone, or methanol, dried, and transferred to a plasma cleaner. Then, the substrate was cleaned using oxygen plasma for 5 minutes, and then the substrate was transferred to a vacuum evaporator.

상기와 같이 준비된 ITO (양극) 위에 본 발명의 화합물들을 도판트로 포함하는 청색 유기 전계 발광 소자를 제작하였다. 소자의 구조는 다음 [표 1] 과 같다.
A blue organic electroluminescent device including the compound of the present invention as a dopant was prepared on the ITO (anode) prepared as described above. The structure of the device is shown in Table 1 below.

HLHL HTLHTL EMLEML ETLETL EILEIL CathodeCathode MaterialsMaterials DS-205DS-205 NPBNPB Host-DopantHost-Dopant Alq3Alq3 LiFLiF AlAl Thickness/ÅThickness / Å 600600 150150 285+15285 + 15 250250 1010 2,0002,000 Evapo.temp/℃Evapo.temp / ℃ 360~370360 to 370 230~240230-240 Host : 240~250
Dopant : 170-180
Host: 240 ~ 250
Dopant: 170-180
240~250240-250 -- --

정공 주입층 (HIL)은 (주) 두산의 DS-205 (아릴아민 유도체)을 600 Å 두께로 하였고, 정공 수송층 (HTL)은 NPB(하기 화학식 5 참조)를 150 Å의 두께로 사용하였다. AND(하기 화학식 6 참조)을 호스트로 사용하였고, 상기 합성예의 화합물을 각각 도판트로 사용하였다. 도판트의 도핑량은 5%로 하였으며, 전자 수송층 (ETL) Alq3(화학식 7 참조)를 250 Å의 두께로 제작하였으며, 전자 주입층 (EIL)은 LiF(화학식 8 참조)를 10 Å으로 제작하였다.
The hole injection layer (HIL) used was DS-205 (arylamine derivative) of Doosan Corp. to a thickness of 600 Å and NPL (see Formula 5 below) to a thickness of 150 Å for a hole transport layer (HTL). AND (see Chemical Formula 6 below) was used as a host, and the compounds of the above synthesis examples were used as dopants, respectively. The doping amount of the dopant was 5%, the electron transport layer (ETL) Alq3 (see Chemical Formula 7) was formed to a thickness of 250 Å, and the electron injection layer (EIL) .

[화학식 5][Chemical Formula 5]

Figure pat00106

Figure pat00106

[화학식 6][Formula 6]

Figure pat00107

Figure pat00107

[화학식 7][Formula 7]

Figure pat00108

Figure pat00108

[화학식 8][Formula 8]

Figure pat00109

Figure pat00109

[비교예 1]Comparative Example 1

와 동일한 방법으로 소자를 제작하였고 발광층의 도펀트로 하기 BD-1(화학식 9 참조)을 사용한 것을 제외하고 상기 실시예 34와 동일한 방법으로 유기발을 평가하였다.
And the organic foot was evaluated in the same manner as in Example 34, except that the following BD-1 (see Chemical Formula 9) was used as a dopant of the light emitting layer.

[화학식 9] [ Chemical Formula 9]

Figure pat00110

Figure pat00110

[실험예][Experimental Example]

발광특성 평가 Luminous Characteristic Evaluation

실시예 1 내지 실시예 35 에서 제조된 본 발명에 따른 유기 발광 화합물과 종래의 발광 화합물을 함유하는 OLED 소자(비교예)의 발광특성을 전류밀도 10 mA/cm2 에서 평가하였다. 그 결과는 표 2와 같다.
The luminescent characteristics of the organic luminescent compound according to the present invention prepared in Examples 1 to 35 and the OLED device containing the conventional luminescent compound (Comparative Example) were evaluated at a current density of 10 mA / cm 2. The results are shown in Table 2.

구분division 화합물compound 전압(V)Voltage (V) Pl peak
(nm)
Pl peak
(nm)
효율(cd/A)Efficiency (cd / A)
실시예 1Example 1 1One 3.93.9 451451 6.66.6 실시예 2Example 2 22 4.14.1 451451 6.36.3 실시예 3Example 3 33 4.04.0 453453 6.26.2 실시예 4Example 4 44 4.24.2 454454 6.46.4 실시예 5Example 5 55 4.24.2 439439 6.86.8 실시예 6Example 6 66 4.04.0 440440 6.86.8 실시예 7Example 7 77 3.73.7 453453 6.46.4 실시예 8Example 8 88 4.04.0 453453 6.56.5 실시예 9Example 9 99 4.04.0 452452 6.96.9 실시예 10Example 10 1010 3.93.9 458458 6.86.8 실시예 11Example 11 1111 3.83.8 459459 6.46.4 실시예 12Example 12 1212 3.73.7 450450 6.86.8 실시예 13Example 13 1313 3.73.7 440440 6.36.3 실시예 14Example 14 1414 3.73.7 448448 6.76.7 실시예 15Example 15 1515 3.93.9 463463 6.46.4 실시예 16Example 16 1616 3.53.5 452452 6.76.7 실시예 17Example 17 1717 3.83.8 451451 6.66.6 실시예 18Example 18 1818 3.83.8 457457 6.76.7 실시예 19Example 19 1919 3.83.8 462462 6.56.5 실시예 20Example 20 2020 3.73.7 451451 6.96.9 실시예 21Example 21 2121 3.53.5 449449 6.86.8 실시예 22Example 22 2222 3.53.5 441441 6.26.2 실시예 23Example 23 2323 3.83.8 443443 6.46.4 실시예 24Example 24 2424 3.83.8 461461 5.95.9 실시예 25Example 25 2525 3.73.7 453453 5.85.8 실시예 26Example 26 2626 3.93.9 452452 6.46.4 실시예 27Example 27 2727 3.93.9 452452 6.56.5 실시예 28Example 28 2828 4.04.0 453453 6.76.7 실시예 29Example 29 2929 4.04.0 458458 6.46.4 실시예 30Example 30 3030 4.24.2 457457 6.36.3 실시예 31Example 31 3131 4.14.1 461461 6.56.5 실시예 32Example 32 3232 4.14.1 451451 6.56.5 실시예 33Example 33 3333 4.24.2 449449 6.36.3 실시예 34Example 34 3434 4.64.6 459459 5.95.9 실시예 35Example 35 3535 4.64.6 455455 5.85.8 비교예Comparative example BD-1BD-1 4.74.7 458458 5.65.6

상술한 바와 같이 본 발명의 아크리딘 구조를 포함하는 신규한 화합물 및 이를 이용한 유기 전계 발광 소자는 열적으로 안정한 본원의 화학식 1로 표시되는 스티릴 구조의 신규 화합물을 합성하고 이를 다층 구조의 유기 전계 발광 소자의 유기 발광층(EML)의 도판트로 사용함으로써 구동전압이 낮아지고 발광효율이 향상되며 수명이 연장될 뿐만 아니라 열 안정성이 우수한 청색 유기 전계 발광 소자를 제공할 수 있는 효과가 있다.
As described above, the novel compound containing an acridine structure of the present invention and the organic electroluminescent device using the same can synthesize a thermally stable novel styryl compound represented by the general formula (1) The use of the organic electroluminescent layer as a dopant of the organic light emitting layer (EML) of the light emitting device can provide a blue organic electroluminescent device having a low driving voltage, improved luminous efficiency, prolonged service life, and excellent thermal stability.

이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시 양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항 들과 그것들의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. something to do. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.

100: 유기 전계 발광 소자 101: 기판
102: 양극 103: 정공 주입층
104: 정공 수송층 105: 발광층
106: 정공 저지층 107: 전자 수송층
108: 전자 주입층 109: 음극
100: organic electroluminescent device 101: substrate
102: Positive electrode 103: Hole injection layer
104: Hole transport layer 105: Light emitting layer
106: hole blocking layer 107: electron transporting layer
108: electron injection layer 109: cathode

Claims (9)

하기 화학식 1로 표시되는 화합물:
[화학식 1]
Figure pat00111

상기 화학식 1에서,
A 및 B는 각각 독립적으로 단일결합, 치환 혹은 비치환된 C6~C60의 아릴렌기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴렌기로 이루어진 군에서 선택되고;
n은 0 또는 1이고, 단 n이 0 일 때 상기 A 및 B는 서로 상이하고, 치환 혹은 비치환된 C6~C60의 아릴렌기 또는 치환 혹은 비치환된 C3~C60의 헤테로아릴렌기이고;
Ar1 및 Ar2는 각각 독립적으로 하기 화학식 2 내지 화학식 4로 이루어진 군에서 선택되는 치환기이며, 상기 Ar1 및 Ar2가 동시에 화학식 4로 표시되는 치환기인 경우를 제외하고;
[화학식 2]
Figure pat00112

[화학식 3]
Figure pat00113

[화학식 4]
Figure pat00114

R1 내지 R10은 각각 독립적으로 치환 혹은 비치환된 C1~C60의 알킬기, 치환 혹은 비치환된 C2~C60의 알케닐기, 치환 혹은 비치환된 C2~C60의 알키닐기, 치환 혹은 비치환된 C6~C60의 아릴기, 치환 혹은 비치환된 C3~C60의 헤테로아릴기, 치환 혹은 비치환된 C1~C60의 알콕시기, 치환 혹은 비치환된 C6~C60의 아릴옥시기, 치환 혹은 비치환된 C7~C60의 아릴알킬기, 치환 혹은 비치환된 C3~C60의 헤테로아릴알킬기, 치환 혹은 비치환된 C3~C60의 시클로알킬기, 치환 혹은 비치환된 C1~C60의 할로겐알킬기, 치환 혹은 비치환된 C1~C60의 헤테로시클로알킬기, 치환 혹은 비치환된 C3~C60 의 알킬실릴기, 치환 혹은 비치환된 C3~C60의 아릴실릴기, 및 치환 혹은 비치환된 C1~C60의 헤테로아릴실릴기로 이루어진 군에서 선택되고;
R1 내지 R8은 각각 인접하는 치환기와 융합(fused)되거나 고리를 형성할 수 있고;
X1 내지 X5는 각각 독립적으로 수소, 중수소, 할로겐, 아미노기, 니트로기, 니트릴기, 치환 혹은 비치환된 C1~C60의 알킬기, 치환 혹은 비치환된 C2~C60의 알케닐기, 치환 혹은 비치환된 C2~C60의 알키닐기, 치환 혹은 비치환된 C6~C60의 아릴기, 치환 혹은 비치환된 C3~C60의 헤테로아릴기, 치환 혹은 비치환된 C1~C60의 알콕시기, 치환 혹은 비치환된 C6~C60의 아릴옥시기, 치환 혹은 비치환된 C6~C60의 알킬아미노기, 치환 혹은 비치환된 C6~C60의 아릴아미노기, 치환 혹은 비치환된 C6~C60의 디아릴아미노기, 치환 혹은 비치환된 C3~C60의 헤테로아릴아미노기, 치환 혹은 비치환된 C2~C60의 디헤테로아릴아미노기, 치환 혹은 비치환된 C7~C60의 아릴알킬기, 치환 혹은 비치환된 C3~C60의 헤테로아릴알킬기, 치환 혹은 비치환된 C3~C60의 시클로알킬기, 치환 혹은 비치환된 C1~C60의 할로겐알킬기, 치환 혹은 비치환된 C1~C60의 헤테로시클로알킬기, 치환 혹은 비치환된 C3~C60 의 알킬실릴기, 치환 혹은 비치환된 C3~C60의 아릴실릴기, 및 치환 혹은 비치환된 C1~C60의 헤테로아릴실릴기로 이루어진 군에서 선택되고;
p, q, r, s 및 t 는 각각 독립적으로 0 내지 4 사이의 정수이다.
A compound represented by the following formula (1):
[Formula 1]
Figure pat00111

In Chemical Formula 1,
A and B are each independently selected from the group consisting of a single bond, a substituted or unsubstituted C 6 -C 60 arylene group and a substituted or unsubstituted C 3 -C 60 heteroarylene group;
n is 0 or 1, provided that when A is 0, A and B are different from each other, and a substituted or unsubstituted C 6 -C 60 arylene group or a substituted or unsubstituted C 3 -C 60 heteroarylene group ego;
Ar 1 and Ar 2 are each independently a substituent selected from the group consisting of Formulas 2 to 4, except that Ar 1 and Ar 2 are substituents represented by Formula 4 at the same time;
(2)
Figure pat00112

(3)
Figure pat00113

[Chemical Formula 4]
Figure pat00114

Each of R 1 to R 10 independently represents a substituted or unsubstituted C 1 to C 60 alkyl group, a substituted or unsubstituted C 2 to C 60 alkenyl group, a substituted or unsubstituted C 2 to C 60 alkynyl group, A substituted or unsubstituted C 6 to C 60 aryl group, a substituted or unsubstituted C 3 to C 60 heteroaryl group, a substituted or unsubstituted C 1 to C 60 alkoxy group, a substituted or unsubstituted C 6 to C 60 aryl group, ~ C 60 of the aryloxy group, a substituted or unsubstituted C 7 ~ C 60 aryl group, a substituted or unsubstituted C 3 ~ C 60 heteroaryl group, a substituted or unsubstituted C 3 ~ cycloalkyl group of C 60 of the , A substituted or unsubstituted C 1 to C 60 halogenalkyl group, a substituted or unsubstituted C 1 to C 60 heterocycloalkyl group, a substituted or unsubstituted C 3 to C 60 alkylsilyl group, a substituted or unsubstituted A C 3 to C 60 arylsilyl group, and a substituted or unsubstituted C 1 to C 60 heteroarylsilyl group;
R 1 to R 8 may each be fused or may form a ring with adjacent substituents;
X 1 to X 5 each independently represent hydrogen, deuterium, a halogen, an amino group, a nitro group, a nitrile group, a substituted or unsubstituted C 1 to C 60 alkyl group, a substituted or unsubstituted C 2 to C 60 alkenyl group, A substituted or unsubstituted C 2 to C 60 alkynyl group, a substituted or unsubstituted C 6 to C 60 aryl group, a substituted or unsubstituted C 3 to C 60 heteroaryl group, a substituted or unsubstituted C 1 to C 60 heteroaryl group, ~ C 60 alkoxy group, a substituted or unsubstituted C 6 ~ C 60 of the aryloxy group, a substituted or unsubstituted C 6 ~ C 60 alkyl group, a substituted or beach aryl group of C 6 ~ C 60 ring, A substituted or unsubstituted C 6 to C 60 diarylamino group, a substituted or unsubstituted C 3 to C 60 heteroarylamino group, a substituted or unsubstituted C 2 to C 60 diheteroarylamino group, a C 7 ~ C 60 when the aryl group, a substituted or unsubstituted C 3 ~ C 60 heteroaryl group, a substituted or unsubstituted C 3 ~ C 60 of the ring A substituted or unsubstituted C 1 to C 60 halogenoalkyl group, a substituted or unsubstituted C 1 to C 60 heterocycloalkyl group, a substituted or unsubstituted C 3 to C 60 alkylsilyl group, a substituted or unsubstituted C 1 to C 60 alkyl group, A substituted C 3 to C 60 arylsilyl group, and a substituted or unsubstituted C 1 to C 60 heteroarylsilyl group;
p, q, r, s and t are each independently an integer of 0 to 4;
제1항에 있어서,
상기 Ar1 및 Ar2 중 하나 이상은 하기 화학식 2a로 표시되는 치환기인 것을 특징으로 하는 화합물.
[화학식 2a]
Figure pat00115
The method of claim 1,
Wherein at least one of Ar 1 and Ar 2 is a substituent represented by the following formula (2a).
(2a)
Figure pat00115
제1항에 있어서,
상기 Ar1 및 Ar2 중 하나 이상은 하기 화학식 3a 또는 화학식 3b로 표시되는 치환기인 것을 특징으로 하는 화합물.
[화학식 3a]
Figure pat00116

[화학식 3b]
Figure pat00117
The method of claim 1,
And at least one of Ar 1 and Ar 2 is a substituent represented by the following formula (3a) or (3b).
[Chemical Formula 3]
Figure pat00116

(3b)
Figure pat00117
제1항에 있어서,
상기 A 및 B로 선택되는 치환 혹은 비치환된 C6~C60의 아릴렌기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴렌기는, 각각 독립적으로 치환 혹은 비치환된 페닐렌, 치환 혹은 비치환된 비페닐렌, 치환 혹은 비치환된 나프틸렌, 치환 혹은 비치환된 플루오레닐렌, 치환 혹은 비치환된 페난트레닐렌, 치환 혹은 비치환된 피리디닐렌, 치환 혹은 비치환된 피리미디닐렌, 치환 혹은 비치환의 피리미다지닐렌, 치환 혹은 비치환의 피라지닐렌, 치환 혹은 비치환된 트리아지닐렌, 치환 혹은 비치환된 퀴놀리닐렌, 치환 혹은 비치환된 이소퀴놀리닐렌, 치환 혹은 비치환의 퀴녹살리닐렌, 치환 혹은 비치환된 카바조릴렌, 및 치환 혹은 비치환의 페난트롤렌으로 이루어진 군에서 선택되며, 상기 치환에 사용되는 치환기 각각은 비치환된 C1~C5의 알킬기 또는 할로겐 원소로 치환된 C1~C5의 알킬기인 것을 특징으로 하는 화합물.
The method of claim 1,
The substituted or unsubstituted C 6 to C 60 arylene group and the substituted or unsubstituted C 3 to C 60 heteroarylene group selected from A and B are each independently substituted or unsubstituted phenylene, substituted or Unsubstituted biphenylene, substituted or unsubstituted naphthylene, substituted or unsubstituted fluorenylene, substituted or unsubstituted phenanthrenylene, substituted or unsubstituted pyridinylene, substituted or unsubstituted pyrimidinylene , Substituted or unsubstituted pyrimidinylene, substituted or unsubstituted pyrazinylene, substituted or unsubstituted triazinylene, substituted or unsubstituted quinolinylene, substituted or unsubstituted isoquinolinylene, substituted or unsubstituted alkenylene raised quinoxaline, a substituted or unsubstituted carbazole crude tolylene, and a substituted or unsubstituted phenanthroline is selected from the group consisting of alkylene, each substituent used in the substituted is unsubstituted C 1 ~ C 5 alkyl group or a halo of A C 1 ~ compound, characterized in that the C 5 alkyl group substituted with an element.
제1항에 있어서,
상기 R1, R4, R9 및 R10로 선택되는 치환 혹은 비치환된 C6~C60의 아릴기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴기는, 각각 독립적으로 치환 혹은 비치환된 페닐, 치환 혹은 비치환된 비페닐, 치환 혹은 비치환된 나프틸, 치환 혹은 비치환된 안트라세닐, 치환 혹은 비치환된 페난트레닐, 치환 혹은 비치환된 플루오레닐, 치환 혹은 비치환된 플루오란테닐, 치환 혹은 비치환된 피리딘, 치환 혹은 비치환된 피리미딘, 치환 혹은 비치환된 트리아진, 치환 혹은 비치환된 피리다진, 치환 혹은 비치환된 피라진, 치환 혹은 비치환된 벤즈이미다졸, 치환 혹은 비치환된 퀴놀린, 치환 혹은 비치환된 이소퀴놀린, 및 치환 혹은 비치환된 카바졸로 이루어진 군에서 선택가능하며, 상기 치환에 사용되는 치환기 각각은 C1~C5의 알킬기 또는 할로겐 원소로 치환된 C1~C5의 알킬기인 것을 특징으로 하는 화합물.
The method of claim 1,
The R 1 , R 4 , R 9 And substituted is selected as R 10, or unsubstituted C 6 ~ C 60 aryl group, and a group heteroaryl substituted or unsubstituted C 3 ~ C 60, each independently represent a substituted or unsubstituted phenyl, substituted or unsubstituted ring Biphenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted anthracenyl, substituted or unsubstituted phenanthrenyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted fluoranthenyl, substituted or unsubstituted Substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrazine, Substituted or unsubstituted isoquinolines, and substituted or unsubstituted carbazoles, and each of the substituents used for the substitution is selected from the group consisting of a C 1 to C 5 alkyl group or a C 1 to C 5 substituted egg Compound, characterized in that group.
(i) 양극, (ii) 음극, 및 (iii) 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 전계 발광 소자로서, 상기 유기물층 중 하나 이상은 제1항 내지 제5항 중 어느 한 항에 따른 화합물을 포함하는 것을 특징으로 하는 유기 전계 발광 소자.An organic electroluminescent device comprising (i) an anode, (ii) a cathode, and (iii) one or more organic layers sandwiched between the anode and the cathode, wherein at least one of the organic layers comprises ≪ / RTI > or a compound according to any one of claims 1 to 10. The organic electroluminescent device according to claim 1, 제 6 항에 있어서,
상기 유기물층은 발광층인 것을 특징으로 하는 유기 전계 발광 소자.
The method according to claim 6,
Wherein the organic material layer is a light emitting layer.
하기 화학식 1로 표시되는 화합물:
[화학식 1]
Figure pat00118

상기 화학식 1에서,
A 및 B는 각각 독립적으로 단일결합, 치환 혹은 비치환된 C6~C60의 아릴렌기 및 치환 혹은 비치환된 C3~C60의 헤테로아릴렌기로 이루어진 군에서 선택되고;
n은 0 또는 1이고, 단 n이 0 일 때 상기 A 및 B가 동시에 단일결합인 경우를 제외하고;
Ar1 및 Ar2는 각각 독립적으로 하기 화학식 2 내지 화학식 4로 이루어진 군에서 선택되는 치환기이며;
이때, 상기 Ar1 및 Ar2 중 적어도 하나는 하기 화학식 3으로 표시되는 치환기이거나, 또는 Ar1 및 Ar2 모두 화학식 2로 표시되는 치환기이며;
단, 상기 Ar1 및 Ar2가 동시에 화학식 4로 표시되는 치환기인 경우를 제외하고;
[화학식 2]
Figure pat00119

[화학식 3]
Figure pat00120

[화학식 4]
Figure pat00121

R1 내지 R10은 각각 독립적으로 치환 혹은 비치환된 C1~C60의 알킬기, 치환 혹은 비치환된 C2~C60의 알케닐기, 치환 혹은 비치환된 C2~C60의 알키닐기, 치환 혹은 비치환된 C6~C60의 아릴기, 치환 혹은 비치환된 C3~C60의 헤테로아릴기, 치환 혹은 비치환된 C1~C60의 알콕시기, 치환 혹은 비치환된 C6~C60의 아릴옥시기, 치환 혹은 비치환된 C7~C60의 아릴알킬기, 치환 혹은 비치환된 C3~C60의 헤테로아릴알킬기, 치환 혹은 비치환된 C3~C60의 시클로알킬기, 치환 혹은 비치환된 C1~C60의 할로겐알킬기, 치환 혹은 비치환된 C1~C60의 헤테로시클로알킬기, 치환 혹은 비치환된 C3~C60 의 알킬실릴기, 치환 혹은 비치환된 C3~C60의 아릴실릴기, 및 치환 혹은 비치환된 C1~C60의 헤테로아릴실릴기로 이루어진 군에서 선택되고;
R1 내지 R8은 각각 인접하는 치환기와 융합(fused)되거나 고리를 형성할 수 있고;
X1 내지 X5는 각각 독립적으로 수소, 중수소, 할로겐, 아미노기, 니트로기, 니트릴기, 치환 혹은 비치환된 C1~C60의 알킬기, 치환 혹은 비치환된 C2~C60의 알케닐기, 치환 혹은 비치환된 C2~C60의 알키닐기, 치환 혹은 비치환된 C6~C60의 아릴기, 치환 혹은 비치환된 C3~C60의 헤테로아릴기, 치환 혹은 비치환된 C1~C60의 알콕시기, 치환 혹은 비치환된 C6~C60의 아릴옥시기, 치환 혹은 비치환된 C6~C60의 알킬아미노기, 치환 혹은 비치환된 C6~C60의 아릴아미노기, 치환 혹은 비치환된 C6~C60의 디아릴아미노기, 치환 혹은 비치환된 C3~C60의 헤테로아릴아미노기, 치환 혹은 비치환된 C2~C60의 디헤테로아릴아미노기, 치환 혹은 비치환된 C7~C60의 아릴알킬기, 치환 혹은 비치환된 C3~C60의 헤테로아릴알킬기, 치환 혹은 비치환된 C3~C60의 시클로알킬기, 치환 혹은 비치환된 C1~C60의 할로겐알킬기, 치환 혹은 비치환된 C1~C60의 헤테로시클로알킬기, 치환 혹은 비치환된 C3~C60 의 알킬실릴기, 치환 혹은 비치환된 C3~C60의 아릴실릴기, 및 치환 혹은 비치환된 C1~C60의 헤테로아릴실릴기로 이루어진 군에서 선택되고;
p, q, r, s 및 t 는 각각 독립적으로 0 내지 4 사이의 정수이다.
A compound represented by the following formula (1):
[Formula 1]
Figure pat00118

In Chemical Formula 1,
A and B are each independently selected from the group consisting of a single bond, a substituted or unsubstituted C 6 -C 60 arylene group and a substituted or unsubstituted C 3 -C 60 heteroarylene group;
n is 0 or 1, except when A and B are single bonds simultaneously when n is 0;
Ar 1 and Ar 2 are each independently a substituent selected from the group consisting of Formulas 2 to 4;
At least one of Ar 1 and Ar 2 may be a substituent represented by Formula 3 below, or both Ar 1 and Ar 2 may be substituents represented by Formula 2;
Except that Ar 1 and Ar 2 are the substituents represented by Formula 4 at the same time;
(2)
Figure pat00119

(3)
Figure pat00120

[Chemical Formula 4]
Figure pat00121

Each of R 1 to R 10 independently represents a substituted or unsubstituted C 1 to C 60 alkyl group, a substituted or unsubstituted C 2 to C 60 alkenyl group, a substituted or unsubstituted C 2 to C 60 alkynyl group, A substituted or unsubstituted C 6 to C 60 aryl group, a substituted or unsubstituted C 3 to C 60 heteroaryl group, a substituted or unsubstituted C 1 to C 60 alkoxy group, a substituted or unsubstituted C 6 to C 60 aryl group, ~ C 60 of the aryloxy group, a substituted or unsubstituted C 7 ~ C 60 aryl group, a substituted or unsubstituted C 3 ~ C 60 heteroaryl group, a substituted or unsubstituted C 3 ~ cycloalkyl group of C 60 of the , A substituted or unsubstituted C 1 to C 60 halogenalkyl group, a substituted or unsubstituted C 1 to C 60 heterocycloalkyl group, a substituted or unsubstituted C 3 to C 60 alkylsilyl group, a substituted or unsubstituted A C 3 to C 60 arylsilyl group, and a substituted or unsubstituted C 1 to C 60 heteroarylsilyl group;
R 1 to R 8 may each be fused or may form a ring with adjacent substituents;
X 1 to X 5 each independently represent hydrogen, deuterium, a halogen, an amino group, a nitro group, a nitrile group, a substituted or unsubstituted C 1 to C 60 alkyl group, a substituted or unsubstituted C 2 to C 60 alkenyl group, A substituted or unsubstituted C 2 to C 60 alkynyl group, a substituted or unsubstituted C 6 to C 60 aryl group, a substituted or unsubstituted C 3 to C 60 heteroaryl group, a substituted or unsubstituted C 1 to C 60 heteroaryl group, ~ C 60 alkoxy group, a substituted or unsubstituted C 6 ~ C 60 of the aryloxy group, a substituted or unsubstituted C 6 ~ C 60 alkyl group, a substituted or beach aryl group of C 6 ~ C 60 ring, A substituted or unsubstituted C 6 to C 60 diarylamino group, a substituted or unsubstituted C 3 to C 60 heteroarylamino group, a substituted or unsubstituted C 2 to C 60 diheteroarylamino group, a C 7 ~ C 60 when the aryl group, a substituted or unsubstituted C 3 ~ C 60 heteroaryl group, a substituted or unsubstituted C 3 ~ C 60 of the ring A substituted or unsubstituted C 1 to C 60 halogenoalkyl group, a substituted or unsubstituted C 1 to C 60 heterocycloalkyl group, a substituted or unsubstituted C 3 to C 60 alkylsilyl group, a substituted or unsubstituted C 1 to C 60 alkyl group, A substituted C 3 to C 60 arylsilyl group, and a substituted or unsubstituted C 1 to C 60 heteroarylsilyl group;
p, q, r, s and t are each independently an integer of 0 to 4;
(i) 양극, (ii) 음극, 및 (iii) 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 전계 발광 소자로서, 상기 유기물층 중 하나 이상은 제8항에 따른 화합물을 포함하는 것을 특징으로 하는 유기 전계 발광 소자.(i) an anode, (ii) a cathode, and (iii) one or more organic layers sandwiched between the anode and the cathode, wherein at least one of the organic layers comprises the compound And an organic light emitting layer.
KR1020130101120A 2013-08-26 2013-08-26 Novel compounds having arcridine structure and organic electroluminescence device using the same KR101434798B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020130101120A KR101434798B1 (en) 2013-08-26 2013-08-26 Novel compounds having arcridine structure and organic electroluminescence device using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020130101120A KR101434798B1 (en) 2013-08-26 2013-08-26 Novel compounds having arcridine structure and organic electroluminescence device using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020110134925A Division KR20130074803A (en) 2011-12-14 2011-12-14 Novel compounds having arcridine structure and organic electroluminescence device using the same

Publications (2)

Publication Number Publication Date
KR20130100255A true KR20130100255A (en) 2013-09-10
KR101434798B1 KR101434798B1 (en) 2014-08-27

Family

ID=49451087

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020130101120A KR101434798B1 (en) 2013-08-26 2013-08-26 Novel compounds having arcridine structure and organic electroluminescence device using the same

Country Status (1)

Country Link
KR (1) KR101434798B1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101120892B1 (en) * 2009-06-19 2012-02-27 주식회사 두산 Acridine derivative and organic electroluminescence device comprising the same

Also Published As

Publication number Publication date
KR101434798B1 (en) 2014-08-27

Similar Documents

Publication Publication Date Title
JP5922766B2 (en) Novel compound and organic electronic device using the same
KR101825405B1 (en) An electroluminescent compound and an electroluminescent device comprising the same
KR20170082459A (en) An electroluminescent compound and an electroluminescent device comprising the same
WO2017043757A1 (en) Organic compound, organic optoelectronic diode, and display device
KR20100108903A (en) Novel compounds for organic electronic material and organic electronic device using the same
KR20100109060A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR20110015836A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR20130059265A (en) Compound for organic electronic element, organic electronic element using the same, and a electronic device thereof
KR20110132721A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR20120009761A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR20120116269A (en) Novel compounds for organic electronic material and organic electroluminescence device using the same
TW201431868A (en) Amine derivatives, organic light-emitting material and organic electroluminescent device using the same
KR20120034140A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR20110120994A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR101408632B1 (en) New compounds and organic electronic device using the same
JP2021525000A (en) Organic light emitting element
KR101597865B1 (en) New compounds and organic electronic device using the same
KR20150092145A (en) Aromatic amine derivative and organic electroluminescent element
KR20120050557A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
JPWO2015182547A1 (en) Fluoranthene derivative, electronic device containing the same, light emitting element and photoelectric conversion element
CN113166171B (en) Heterocyclic compound and organic light-emitting device comprising the same
KR20110134581A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
KR101298349B1 (en) Organic compound and organic electroluminescent devices using the same
JP2021524154A (en) Organic light emitting element
KR20130074803A (en) Novel compounds having arcridine structure and organic electroluminescence device using the same

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee